525 results on '"Carlotta Sacerdote"'
Search Results
2. Risk prediction models for endometrial cancer: development and validation in an international consortium
- Author
-
Joy Shi, Peter Kraft, Bernard A Rosner, Yolanda Benavente, Amanda Black, Louise A Brinton, Chu Chen, Megan A Clarke, Linda S Cook, Laura Costas, Luigino Dal Maso, Jo L Freudenheim, Jon Frias-Gomez, Christine M Friedenreich, Montserrat Garcia-Closas, Marc T Goodman, Lisa Johnson, Carlo La Vecchia, Fabio Levi, Jolanta Lissowska, Lingeng Lu, Susan E McCann, Kirsten B Moysich, Eva Negri, Kelli O'Connell, Fabio Parazzini, Stacey Petruzella, Jerry Polesel, Jeanette Ponte, Timothy R Rebbeck, Peggy Reynolds, Fulvio Ricceri, Harvey A Risch, Carlotta Sacerdote, Veronica W Setiawan, Xiao-Ou Shu, Amanda B Spurdle, Britton Trabert, Penelope M Webb, Nicolas Wentzensen, Lynne R Wilkens, Wang Hong Xu, Hannah P Yang, Herbert Yu, Mengmeng Du, and Immaculata De Vivo
- Subjects
prediction model ,Cancer Research ,Oncology ,Settore MED/06 - Oncologia Medica ,Settore MED/42 - Igiene Generale e Applicata ,endometrial cancer ,endometrium ,cancer risk ,Settore MED/40 - Ginecologia e Ostetricia ,Settore MED/01 - Statistica Medica - Abstract
Background Endometrial cancer risk stratification may help target interventions, screening, or prophylactic hysterectomy to mitigate the rising burden of this cancer. However, existing prediction models have been developed in select cohorts and have not considered genetic factors. Methods We developed endometrial cancer risk prediction models using data on postmenopausal White women aged 45-85 years from 19 case-control studies in the Epidemiology of Endometrial Cancer Consortium (E2C2). Relative risk estimates for predictors were combined with age-specific endometrial cancer incidence rates and estimates for the underlying risk factor distribution. We externally validated the models in 3 cohorts: Nurses’ Health Study (NHS), NHS II, and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Results Area under the receiver operating characteristic curves for the epidemiologic model ranged from 0.64 (95% confidence interval [CI] = 0.62 to 0.67) to 0.69 (95% CI = 0.66 to 0.72). Improvements in discrimination from the addition of genetic factors were modest (no change in area under the receiver operating characteristic curves in NHS; PLCO = 0.64 to 0.66). The epidemiologic model was well calibrated in NHS II (overall expected-to-observed ratio [E/O] = 1.09, 95% CI = 0.98 to 1.22) and PLCO (overall E/O = 1.04, 95% CI = 0.95 to 1.13) but poorly calibrated in NHS (overall E/O = 0.55, 95% CI = 0.51 to 0.59). Conclusions Using data from the largest, most heterogeneous study population to date (to our knowledge), prediction models based on epidemiologic factors alone successfully identified women at high risk of endometrial cancer. Genetic factors offered limited improvements in discrimination. Further work is needed to refine this tool for clinical or public health practice and expand these models to multiethnic populations.
- Published
- 2023
3. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study
- Author
-
Esmée C. de Baat, Elizabeth A.M. Feijen, Raoul C. Reulen, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bardi, Fabiën N. Belle, Julianne Byrne, Elvira C. van Dalen, Ghazi Debiche, Ibrahima Diallo, Desiree Grabow, Lars Hjorth, Momcilo Jankovic, Claudia E. Kuehni, Gill Levitt, Damien Llanas, Jacqueline Loonen, Lorna Z. Zaletel, Milena M. Maule, Lucia Miligi, Helena J.H. van der Pal, Cécile M. Ronckers, Carlotta Sacerdote, Roderick Skinner, Zsuzsanna Jakab, Cristina Veres, Nadia Haddy, David L. Winter, Florent de Vathaire, Michael M. Hawkins, and Leontien C.M. Kremer
- Subjects
Heart Failure ,Cancer Research ,European People ,Antibiotics, Antineoplastic ,360 Soziale Probleme, Sozialdienste ,610 Medicine & health ,Middle Aged ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,All institutes and research themes of the Radboud University Medical Center ,Oncology ,Cancer Survivors ,360 Social problems & social services ,Risk Factors ,Neoplasms ,Case-Control Studies ,Humans ,Anthracyclines ,610 Medizin und Gesundheit ,Child - Abstract
PURPOSE Heart failure (HF) is a potentially life-threatening complication of treatment for childhood cancer. We evaluated the risk and risk factors for HF in a large European study of long-term survivors. Little is known of the effects of low doses of treatment, which is needed to improve current treatment protocols and surveillance guidelines. METHODS This study includes the PanCareSurFup and ProCardio cohort of ≥ 5-year childhood cancer survivors diagnosed between 1940 and 2009 in seven European countries (N = 42,361). We calculated the cumulative incidence of HF and conducted a nested case-control study to evaluate detailed treatment-related risk factors. RESULTS The cumulative incidence of HF was 2% (95% CI, 1.7 to 2.2) by age 50 years. The case-control study (n = 1,000) showed that survivors who received a mean heart radiation therapy (RT) dose of 5 to < 15 Gy have an increased risk of HF (odds ratio, 5.5; 95% CI, 2.5 to 12.3), when compared with no heart RT. The risk associated with doses 5 to < 15 Gy increased with exposure of a larger heart volume. In addition, the HF risk increased in a linear fashion with higher mean heart RT doses. Regarding total cumulative anthracycline dose, survivors who received ≥ 100 mg/m2 had a substantially increased risk of HF and survivors treated with a lower dose showed no significantly increased risk of HF. The dose-response relationship appeared quadratic with higher anthracycline doses. CONCLUSION Survivors who received a mean heart RT dose of ≥ 5 Gy have an increased risk of HF. The risk associated with RT increases with larger volumes exposed. Survivors treated with < 100 mg/m2 total cumulative anthracycline dose have no significantly increased risk of HF. These new findings might have consequences for new treatment protocols for children with cancer and for cardiomyopathy surveillance guidelines.
- Published
- 2023
4. Coffee consumption and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium (E2C2)
- Author
-
Marta Crous-Bou, Mengmeng Du, Marc J Gunter, Veronica W Setiawan, Leo J Schouten, Xiao-ou Shu, Nicolas Wentzensen, Kimberly A Bertrand, Linda S Cook, Christine M Friedenreich, Susan M Gapstur, Marc T Goodman, Torukiri I Ibiebele, Carlo La Vecchia, Fabio Levi, Linda M Liao, Eva Negri, Susan E McCann, Kelly O’Connell, Julie R Palmer, Alpa V Patel, Jeanette Ponte, Peggy Reynolds, Carlotta Sacerdote, Rashmi Sinha, Amanda B Spurdle, Britton Trabert, Piet A van den Brandt, Penelope M Webb, Stacey Petruzella, Sara H Olson, Immaculata De Vivo, Epidemiologie, and RS: GROW - R1 - Prevention
- Subjects
Nutrition and Dietetics ,Medicine (miscellaneous) - Abstract
BACKGROUND: Epidemiological studies suggest that coffee consumption may be inversely associated with risk of endometrial cancer (EC), the most common gynecological malignancy in developed countries. Furthermore, coffee consumption may lower circulating levels of estrogen and insulin, hormones implicated in endometrial carcinogenesis. Antioxidants and other chemopreventive compounds in coffee may have anticarcinogenic effects. Based on available meta-analyses, the World Cancer Research Fund concluded that consumption of coffee probably protects against EC.OBJECTIVE: Our main aim was to examine the association between coffee consumption and EC risk by combining individual-level data in a pooled analysis. We also sought to evaluate potential effect modification by other risk factors of EC.PATIENTS AND METHODS: We combined individual-level data from 19 epidemiologic studies (6 cohort, 13 case-control) of 12,159 endometrial cancer cases and 27,479 controls from the Epidemiology of Endometrial Cancer Consortium (E2C2). Logistic regression was used to calculate odds ratios (OR) and their corresponding 95% confidence intervals (CI). All models were adjusted for potential confounders including age, race, body mass index, smoking status, diabetes status, study design and study site.RESULTS: Coffee drinkers had a lower risk of EC compared to non-coffee drinkers (multi-adjusted OR = 0.87, 95% CI = 0.79,0.95). There was a dose-response relationship between higher coffee consumption and lower risk of EC: compared to non-coffee drinkers, the adjusted pooled ORs for those who drank 1, 2-3 and more than 4 cups/day were 0.90 (95% CI = 0.82,1.00), 0.86 (95% CI = 0.78,0.95), and 0.76 (95% CI = 0.66,0.87), respectively (p for trend < 0.001). The inverse association between coffee consumption and EC risk was stronger in participants with body mass index (BMI) over 25 kg/m2.CONCLUSION: The results of the largest analysis to date pooling individual-level data further support the potentially beneficial health effects of coffee consumption in relation to EC, especially among females with higher BMI.
- Published
- 2023
5. Body shape phenotypes of multiple anthropometric traits and cancer risk: a multi-national cohort study
- Author
-
Anja M. Sedlmeier, Vivian Viallon, Pietro Ferrari, Laia Peruchet-Noray, Emma Fontvieille, Amina Amadou, Nazlisadat Seyed Khoei, Andrea Weber, Hansjörg Baurecht, Alicia K. Heath, Kostas Tsilidis, Rudolf Kaaks, Verena Katzke, Elif Inan-Eroglu, Matthias B. Schulze, Kim Overvad, Catalina Bonet, Esther Ubago-Guisado, María-Dolores Chirlaque, Eva Ardanaz, Aurora Perez-Cornago, Valeria Pala, Rosario Tumino, Carlotta Sacerdote, Fabrizio Pasanisi, Kristin B. Borch, Charlotta Rylander, Elisabete Weiderpass, Marc J. Gunter, Béatrice Fervers, Michael F. Leitzmann, Heinz Freisling, [Sedlmeier, Anja M. M.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Weber, Andrea] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Baurecht, Hansjoerg] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Leitzmann, Michael F. F.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany, [Viallon, Vivian] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Ferrari, Pietro] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Peruchet-Noray, Laia] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Fontvieille, Emma] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Weiderpass, Elisabete] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Gunter, Marc J. J.] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Freisling, Heinz] Int Agcy Res Canc IARC, Nutr & Metab Branch, Lyon, France, [Peruchet-Noray, Laia] Univ Barcelona, Fac Med, Dept Clin Sci, Barcelona, Spain, [Amadou, Amina] Ctr Leon Berard, Dept Prevent Canc Environm, Lyon, France, [Fervers, Beatrice] Ctr Leon Berard, Dept Prevent Canc Environm, Lyon, France, [Amadou, Amina] INSERM, UMR1296 Radiat Def, Hlth, Environm, Lyon, France, [Fervers, Beatrice] INSERM, UMR1296 Radiat Def, Hlth, Environm, Lyon, France, [Seyed Khoei, Nazlisadat] Univ Vienna, Fac Life Sci, Dept Nutr Sci, Vienna, Austria, [Heath, Alicia K. K.] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England, [Tsilidis, Kostas] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England, [Tsilidis, Kostas] Univ Ioannina, Dept Hyg & Epidemiol, Sch Med, Ioannina, Greece, [Kaaks, Rudolf] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany, [Katzke, Verena] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany, [Inan-Eroglu, Elif] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, Nuthetal, Germany, [Schulze, Matthias B. B.] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Epidemiol, Nuthetal, Germany, [Overvad, Kim] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark, [Bonet, Catalina] Catalan Inst Oncol ICO, Unit Nutr & Canc, Barcelona, Spain, [Bonet, Catalina] Bellvitge Biomed Res Inst IDIBELL, Canc Prevent & Palliat Care Program, Nutr & Canc Grp, Epidemiol,Publ Hlth, Barcelona, Spain, [Ubago-Guisado, Esther] Escuela Andaluza Salud Publ EASP, Granada, Spain, [Ubago-Guisado, Esther] Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain, [Ubago-Guisado, Esther] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Chirlaque, Maria-Dolores] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Ardanaz, Eva] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain, [Chirlaque, Maria-Dolores] Reg Hlth Council, Dept Epidemiol, Murcia, Spain, [Chirlaque, Maria-Dolores] Murcia Univ, IMIB Arrixaca, Murcia, Spain, [Ardanaz, Eva] IdiSNA, Navarra Publ Hlth Inst, Pamplona, Spain, [Perez-Cornago, Aurora] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England, [Pala, Valeria] Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy, [Tumino, Rosario] AIRE ONLUS, Hyblean Assoc Epidemiol Res, Ragusa, Italy, [Sacerdote, Carlotta] Citta Salute & Sci Univ Hosp, Unit Canc Epidemiol, Turin, Italy, [Pasanisi, Fabrizio] Feder II Univ Hosp, Dept Clin Med & Surg, Clin Nutr Unit, Naples, Italy, [Borch, Kristin B. B.] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Commun Med, Tromso, Norway, [Rylander, Charlotta] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Commun Med, Tromso, Norway, French National Cancer Institute (l'Institut National du Cancer), International Agency for Research on Cancer (IARC), Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society (Denmark), Ligue Contre le Cancer (France), Institut Gustave Roussy (France), Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (INSERM) (France), German Cancer Aid (Germany), German Cancer Research Center (DKFZ) (Germany), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) (Germany), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy (Italy), Compagnia di San Paolo (Italy), National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS) (The Netherlands), Netherlands Cancer Registry (NKR) (The Netherlands), LK Research Funds (The Netherlands), Dutch Prevention Funds (The Netherlands), Dutch ZON (Zorg Onderzoek Nederland) (The Netherlands), World Cancer Research Fund (WCRF) (The Netherlands), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII) (Spain), Regional Government of Andalucia (Spain), Regional Government of Asturias (Spain), Regional Government of Basque Country (Spain), Regional Government of Murcia (Spain), Regional Government of Navarra (Spain), Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society (Sweden), Swedish Research Council (Sweden), County Council of Skane (Sweden), County Council of Vaesterbotten (Sweden), Cancer Research UK (United Kingdom), and Medical Research Council (United Kingdom)
- Subjects
Cancer Research ,Oncology ,Height ,Fat ,Physical-activity ,Obesity ,Esophageal ,Adenocarcinoma ,Metaanalysis ,Weight ,Nutrition ,Validity - Abstract
Background Classical anthropometric traits may fail to fully represent the relationship of weight, adiposity, and height with cancer risk. We investigated the associations of body shape phenotypes with the risk of overall and site-specific cancers. Methods We derived four distinct body shape phenotypes from principal component (PC) analysis on height, weight, body mass index (BMI), waist (WC) and hip circumferences (HC), and waist-to-hip ratio (WHR). The study included 340,152 men and women from 9 European countries, aged mostly 35–65 years at recruitment (1990–2000) in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results After a median follow-up of 15.3 years, 47,110 incident cancer cases were recorded. PC1 (overall adiposity) was positively associated with the risk of overall cancer, with a HR per 1 standard deviation (SD) increment equal to 1.07 (95% confidence interval 1.05 to 1.08). Positive associations were observed with 10 cancer types, with HRs (per 1 SD) ranging from 1.36 (1.30–1.42) for endometrial cancer to 1.08 (1.03–1.13) for rectal cancer. PC2 (tall stature with low WHR) was positively associated with the risk of overall cancer (1.03; 1.02–1.04) and five cancer types which were not associated with PC1. PC3 (tall stature with high WHR) was positively associated with the risk of overall cancer (1.04; 1.03–1.05) and 12 cancer types. PC4 (high BMI and weight with low WC and HC) was not associated with overall risk of cancer (1.00; 0.99–1.01). Conclusions In this multi-national study, distinct body shape phenotypes were positively associated with the incidence of 17 different cancers and overall cancer.
- Published
- 2022
6. Protein and amino acid intakes in relation to prostate cancer risk and mortality—A prospective study in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Julie A. Schmidt, Inge Huybrechts, Kim Overvad, Anne Kirstine Eriksen, Anne Tjønneland, Rudolf Kaaks, Verena Katzke, Matthias B. Schulze, Valeria Pala, Carlotta Sacerdote, Rosario Tumino, Bas Bueno‐de‐Mesquita, Maria‐Jose Sánchez, José M. Huerta, Aurelio Barricarte, Pilar Amiano, Antonio Agudo, Anders Bjartell, Tanja Stocks, Elin Thysell, Maria Wennberg, Elisabete Weiderpass, Ruth C. Travis, Timothy J. Key, and Aurora Perez‐Cornago
- Subjects
Male ,Cancer Research ,CROSS-SECTIONAL ANALYSIS ,EGG INTAKE ,dietary protein intakes ,Risk Factors ,GROWTH-FACTOR-I ,Humans ,DIETARY QUESTIONNAIRES ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Amino Acids ,ONE-CARBON METABOLISM ,METAANALYSIS ,Cancer och onkologi ,prostate cancer mortality ,MEAT-EATERS ,Prostatic Neoplasms ,ASSOCIATION ,dietary amino acid intakes ,Diet ,IGF-I ,Oncology ,prostate cancer incidence ,Cancer and Oncology ,tumour subtypes ,RESTRICTION - Abstract
BACKGROUND: The association between protein intake and prostate cancer risk remains unclear.AIMS: To prospectively investigate the associations of dietary intakes of total protein, protein from different dietary sources, and amino acids with prostate cancer risk and mortality.METHODS: In 131,425 men from the European Prospective Investigation into Cancer and Nutrition, protein and amino acid intakes were estimated using validated dietary questionnaires. Multivariable-adjusted Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).RESULTS: During a mean follow-up of 14.2 years, 6939 men were diagnosed with prostate cancer and 914 died of the disease. Dairy protein was positively associated with overall prostate cancer risk in the three highest fifths compared to the lowest (HR Q3 =1.14 (95% CI 1.05-1.23); HR Q 4=1.09 (1.01-1.18); HR Q5 =1.10 (1.02-1.19)); similar results were observed for yogurt protein (HR Q3 =1.14 (1.05-1.24); HR Q4 =1.09 (1.01-1.18); HR Q5 =1.12 (1.04-1.21)). For egg protein intake and prostate cancer mortality, no association was observed by fifths, but there was suggestive evidence of a positive association in the analysis per standard deviation increment. There was no strong evidence of associations with different tumour subtypes. DISCUSSION: Considering the weak associations and many tests, the results must be interpreted with caution.CONCLUSION: This study does not provide strong evidence for an association of intakes of total protein, protein from different dietary sources or amino acids with prostate cancer risk or mortality. However, our results may suggest some weak positive associations, which need to be confirmed in large-scale, pooled analyses of prospective data.
- Published
- 2022
7. Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort ( <scp>EPIC</scp> )
- Author
-
Yahya Mahamat‐Saleh, Marie Al‐Rahmoun, Gianluca Severi, Reza Ghiasvand, Marit B. Veierod, Saverio Caini, Domenico Palli, Edoardo Botteri, Carlotta Sacerdote, Fulvio Ricceri, Marko Lukic, Maria J. Sánchez, Valeria Pala, Rosario Tumino, Paolo Chiodini, Pilar Amiano, Sandra Colorado‐Yohar, María‐Dolores Chirlaque, Eva Ardanaz, Catalina Bonet, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Kim Overvad, Christina C. Dahm, Christian S. Antoniussen, Anne Tjønneland, Cecilie Kyrø, Bas Bueno‐de‐Mesquita, Jonas Manjer, Malin Jansson, Anders Esberg, Nagisa Mori, Pietro Ferrari, Elisabete Weiderpass, Marie‐Christine Boutron‐Ruault, Marina Kvaskoff, Mahamat-Saleh, Yahya, Al-Rahmoun, Marie, Severi, Gianluca, Ghiasvand, Reza, Veierod, Marit B, Caini, Saverio, Palli, Domenico, Botteri, Edoardo, Sacerdote, Carlotta, Ricceri, Fulvio, Lukic, Marko, Sánchez, Maria J, Pala, Valeria, Tumino, Rosario, Chiodini, Paolo, Amiano, Pilar, Colorado-Yohar, Sandra, Chirlaque, María-Dolore, Ardanaz, Eva, Bonet, Catalina, Katzke, Verena, Kaaks, Rudolf, Schulze, Matthias B, Overvad, Kim, Dahm, Christina C, Antoniussen, Christian S, Tjønneland, Anne, Kyrø, Cecilie, Bueno-de-Mesquita, Ba, Manjer, Jona, Jansson, Malin, Esberg, Ander, Mori, Nagisa, Ferrari, Pietro, Weiderpass, Elisabete, Boutron-Ruault, Marie-Christine, and Kvaskoff, Marina
- Subjects
Male ,Cancer och onkologi ,Cancer Research ,Skin Neoplasms ,Alcohol Drinking ,alcohol ,keratinocyte cancers ,Public Health, Global Health, Social Medicine and Epidemiology ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,cutaneous melanoma ,cohort studies ,Oncology ,Carcinoma, Basal Cell ,Risk Factors ,Cancer and Oncology ,Carcinoma, Squamous Cell ,epidemiology ,Humans ,Female ,Prospective Studies ,Melanoma ,cohort studie - Abstract
Experimental evidence suggests that alcohol induces cutaneous carcinogenesis, yet epidemiological studies on the link between alcohol intake and skin cancer have been inconsistent. The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort initiated in 1992 in 10 European countries. Alcohol intake at baseline and average lifetime alcohol intake were assessed using validated country-specific dietary and lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in Cox models. A total of 14 037 skin cancer cases (melanoma: n = 2457; basal-cell carcinoma (BCC): n = 8711; squamous-cell carcinoma (SCC): n = 1928; unknown: n = 941) were identified among 450 112 participants (average follow-up: 15 years). Baseline alcohol intake was positively associated with SCC (>15 vs 0.1-4.9 g/day: HR = 1.44, 95% CI = 1.17-1.77; Ptrend = .001), BCC (HR = 1.12, 95% CI = 1.01-1.23; Ptrend = .04), and melanoma risks in men (HR = 1.17, 95% CI = 0.95-1.44; Ptrend = .17), while associations were more modest in women (SCC: HR = 1.09, 95% CI = 0.90-1.30; Ptrend = .13; BCC: HR = 1.08, 95% CI = 1.00-1.17,Ptrend = .03; melanoma: HR = 0.93, 95% CI = 0.80-1.08, Ptrend = .13). Associations were similar for lifetime alcohol intake, with an attenuated linear trend. Lifetime liquor/spirit intake was positively associated with melanoma (fourth vs first quartile: HR = 1.47, 95% CI = 1.08-1.99; Ptrend = .0009) and BCC risks in men (HR = 1.17, 95% CI = 1.04-1.31;Ptrend = .14). Baseline and lifetime intakes of wine were associated with BCC risk (HR = 1.25 in men; HR = 1.11-1.12; in women). No statistically significant associations were found between beverage types and SCC risk. Intake of beer was not associated with skin cancer risk. Our study suggests positive relationships between alcohol intake and skin cancer risk, which may have important implications for the primary prevention of skin cancer. What's new? Drinking alcohol can make the skin more sensitive to sunlight and vulnerable to skin cancer. Here, the authors conducted a large prospective cohort study to evaluate whether alcohol consumption correlates with skin cancer risk. Among the 450 112 participants, there were 2457 cases of melanoma, 8711 of basal cell carcinoma, and 1928 of squamous cell carcinoma. There was a positive association between alcohol and all three cancer types, stronger in men than in women. The association varied somewhat by beverage type.
- Published
- 2022
8. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
- Author
-
Raoul C. Reulen, David L. Winter, Ibrahim Diallo, Cristina Veres, Damien Llanas, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bárdi, Elizabeth A.M. Feijen, Daniela Alessi, Miranda M. Fidler-Benaoudia, Stine Høgsholt, Jop C. Teepen, Helena Linge, Nadia Haddy, Julianne Byrne, Ghazi Debiche, Desiree Grabow, Thorgerdur Gudmundsdottir, Romain Fauchery, Wael Zrafi, Gisela Michel, Hilde Øfstaas, Peter Kaatsch, Giao Vu-Bezin, Helen Jenkinson, Melanie Kaiser, Roderick Skinner, Trevor Cole, Nicolas Waespe, Grit Sommer, Susanne Nordenfelt, Momcilo Jankovic, Tuomas Lähteenmäki Taalas, Milena M. Maule, Helena J.H. van der Pal, Cécile M. Ronckers, Flora E. van Leeuwen, Judith L. Kok, Monica Terenziani, Maria Winther Gunnes, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Claudia E. Kuehni, Jeanette Falck Winther, Leontien C.M. Kremer, Lars Hjorth, Florent de Vathaire, and Michael M. Hawkins
- Subjects
Cancer Research ,Oncology - Abstract
PURPOSE Radiation to the bone and exposure to alkylating agents increases the risk of bone cancer among survivors of childhood cancer, but there is uncertainty regarding the risks of bone tissue radiation doses below 10 Gy and the dose-response relationship for specific types of chemotherapy. METHODS Twelve European countries contributed 228 cases and 228 matched controls to a nested case-control study within a cohort of 69,460 5-year survivors of childhood cancer. Odds ratios (ORs) of developing bone cancer for different levels of cumulative radiation exposure and cumulative doses of specific types of chemotherapy were calculated. Excess ORs were calculated to investigate the shape and extent of any dose-response relationship. RESULTS The OR associated with bone tissue exposed to 1-4 Gy was 4.8-fold (95% CI, 1.2 to 19.6) and to 5-9 Gy was 9.6-fold (95% CI, 2.4 to 37.4) compared with unexposed bone tissue. The OR increased linearly with increasing dose of radiation ( Ptrend < .001) up to 78-fold (95% CI, 9.2 to 669.9) for doses of ≥40 Gy. For cumulative alkylating agent doses of 10,000-19,999 and ≥20,000 mg/m2, the radiation-adjusted ORs were 7.1 (95% CI, 2.2 to 22.8) and 8.3 (95% CI, 2.8 to 24.4), respectively, with independent contributions from each of procarbazine, ifosfamide, and cyclophosphamide. Other cytotoxics were not associated with bone cancer. CONCLUSION To our knowledge, we demonstrate—for the first time—that the risk of bone cancer is increased 5- to 10-fold after exposure of bone tissue to cumulative radiation doses of 1-9 Gy. Alkylating agents exceeding 10,000 mg/m2 increase the risk 7- to 8-fold, particularly following procarbazine, ifosfamide, and cyclophosphamide. These substantially elevated risks should be used to develop/update clinical follow-up guidelines and survivorship care plans.
- Published
- 2023
9. The association between body fatness and mortality among breast cancer survivors:results from a prospective cohort study
- Author
-
Catalina Bonet, Marta Crous-Bou, Konstantinos K. Tsilidis, Marc J. Gunter, Rudolf Kaaks, Matthias B. Schulze, Renée T. Fortner, Christian S. Antoniussen, Christina C. Dahm, Lene Mellemkjær, Anne Tjønneland, Pilar Amiano, Eva Ardanaz, Sandra M. Colorado-Yohar, Miguel Rodriguez-Barranco, Sandar Tin Tin, Claudia Agnoli, Giovanna Masala, Salvatore Panico, Carlotta Sacerdote, Anne M. May, Kristin Benjaminsen Borch, Charlotta Rylander, Guri Skeie, Sofia Christakoudi, Dagfinn Aune, Elisabete Weiderpass, Laure Dossus, Elio Riboli, and Antonio Agudo
- Subjects
Epidemiology - Abstract
Evidence linking body fatness to breast cancer (BC) prognosis is limited. While it seems that excess adiposity is associated with poorer BC survival, there is uncertainty over whether weight changes reduce mortality. This study aimed to assess the association between body fatness and weight changes pre- and postdiagnosis and overall mortality and BC-specific mortality among BC survivors. Our study included 13,624 BC survivors from the European Prospective Investigation into Cancer and Nutrition (EPIC) study, with a mean follow-up of 8.6 years after diagnosis. Anthropometric data were obtained at recruitment for all cases and at a second assessment during follow-up for a subsample. We measured general obesity using the body mass index (BMI), whereas waist circumference and A Body Shape Index were used as measures of abdominal obesity. The annual weight change was calculated for cases with two weight assessments. The association with overall mortality and BC-specific mortality were based on a multivariable Cox and Fine and Gray models, respectively. We performed Mendelian randomization (MR) analysis to investigate the potential causal association. Five-unit higher BMI prediagnosis was associated with a 10% (95% confidence interval: 5–15%) increase in overall mortality and 7% (0–15%) increase in dying from BC. Women with abdominal obesity demonstrated a 23% (11–37%) increase in overall mortality, independent of the association of BMI. Results related to weight change postdiagnosis suggested a U-shaped relationship with BC-specific mortality, with higher risk associated with losing weight or gaining > 2% of the weight annually. MR analyses were consistent with the identified associations. Our results support the detrimental association of excess body fatness on the survival of women with BC. Substantial weight changes postdiagnosis may be associated with poorer survival.
- Published
- 2023
10. A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study
- Author
-
Jakub G. Sobiecki, Fumiaki Imamura, Courtney R. Davis, Stephen J. Sharp, Albert Koulman, Jonathan M. Hodgson, Marcela Guevara, Matthias B. Schulze, Ju-Sheng Zheng, Claudia Agnoli, Catalina Bonet, Sandra M. Colorado-Yohar, Guy Fagherazzi, Paul W. Franks, Thomas E. Gundersen, Franziska Jannasch, Rudolf Kaaks, Verena Katzke, Esther Molina-Montes, Peter M. Nilsson, Domenico Palli, Salvatore Panico, Keren Papier, Olov Rolandsson, Carlotta Sacerdote, Anne Tjønneland, Tammy Y. N. Tong, Yvonne T. van der Schouw, John Danesh, Adam S. Butterworth, Elio Riboli, Karen J. Murphy, Nicholas J. Wareham, Nita G. Forouhi, Sobiecki, Jakub G [0000-0003-2641-2313], Imamura, Fumiaki [0000-0002-6841-8396], Davis, Courtney R [0000-0002-3866-2603], Sharp, Stephen J [0000-0003-2375-1440], Koulman, Albert [0000-0001-9998-051X], Hodgson, Jonathan M [0000-0001-6184-7764], Guevara, Marcela [0000-0001-9242-6364], Schulze, Matthias B [0000-0002-0830-5277], Zheng, Ju-Sheng [0000-0001-6560-4890], Agnoli, Claudia [0000-0003-4472-1179], Colorado-Yohar, Sandra M [0000-0002-6700-0780], Fagherazzi, Guy [0000-0001-5033-5966], Franks, Paul W [0000-0002-0520-7604], Jannasch, Franziska [0000-0003-3478-4758], Katzke, Verena [0000-0002-6509-6555], Molina-Montes, Esther [0000-0002-0428-2426], Nilsson, Peter M [0000-0002-5652-8459], Papier, Keren [0000-0002-4102-6835], Sacerdote, Carlotta [0000-0002-8008-5096], Tjønneland, Anne [0000-0003-4385-2097], Tong, Tammy YN [0000-0002-0284-8959], van der Schouw, Yvonne T [0000-0002-4605-435X], Butterworth, Adam S [0000-0002-6915-9015], Riboli, Elio [0000-0001-6795-6080], Wareham, Nicholas J [0000-0003-1422-2993], Forouhi, Nita G [0000-0002-5041-248X], Apollo - University of Cambridge Repository, Sobiecki, Jakub G, Imamura, Fumiaki, Davis, Courtney R, Sharp, Stephen J, and Forouhi, Nita G
- Subjects
Adult ,Clinical Trials and Supportive Activities ,32 Biomedical and Clinical Sciences ,Endocrinology and Diabetes ,Diet, Mediterranean ,Cohort Studies ,Diabetes Mellitus, Type 2/diagnosis ,Risk Factors ,Clinical Research ,Mediterranean diet ,Neoplasms ,Humans ,Neoplasms/complications ,Obesity ,nutritional biomarker score ,Metabolic and endocrine ,Nutrition ,Cancer ,Nutrition and Dietetics ,Prevention ,Diabetes ,Australia ,42 Health Sciences ,General Medicine ,Näringslära ,Diabetes Mellitus, Type 2 ,Endokrinologi och diabetes ,3210 Nutrition and Dietetics ,type 2 diabetes ,Biomarkers - Abstract
The MedLey trial was funded by a National Health and Medical Research Council Grant (#APP1050949 to KJM). The InterAct project was funded by the EU FP6 programme (grant number LSHM_CT_2006_037197 to NJW). Biomarker measurements for carotenoids were funded jointly by the InterAct project, the EPIC-CVD project, and the MRC Cambridge Initiative (RG71466 and SJAH/004 to NJW, NGF, JD, AB). EPIC-CVD has been supported by the UK Medical Research Council (MR/L003120/1 to ASB and JD), the British Heart Foundation (RG/13/13/30194 and RG/18/13/33946 to ASB and JD), the European Commission Framework Programme 7 (HEALTH -F2-2012-279233 to ASB and JD), the European Research Council (268834 to ASB and JD), and the National Institute for Health Research (NIHR; Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust, BRC-1215-20014 to ASB and JD). This work was also supported by Health Data Research UK (to ASB and JD), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), and Wellcome. The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Ge'ne'rale de l'Education Nationale, Institut National de la Sante' et de la Recherche Me'dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Iblea Ricerca Epidemiologica (A.I.R.E. - ONLUS) Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di San Paolo, National Research Council and Sicilian Regional Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands~Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluci'a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology -ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (14136 to NJW; C8221/A29017), Medical Research Council (1000143 to NJW; MR/M012190/1) (United Kingdom). JGS was supported by the MRC PhD studentship. NJW, NGF, and FI acknowledge funding from the Medical Research Council Epidemiology Unit (MC_UU_00006/1, MC_UU_00006/3); and NJW, NGF and AK from the NIHR Cambridge Biomedical Research Centre (IS-BRC-1215-20014; NIHR203312). NGF and JD are NIHR Senior Investigators. JD holds a British Heart Foundation Professorship. MBS acknowledges funding from the Federal Ministry of Education and Research and the State of Brandenburg (DZD grant 82DZD03D03). JSZ has received funding from Westlake University (No YSYY0209) and European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 701708. PWF has received funding from Novo Nordisk, Swedish Diabetes Association, Swedish Heart-Lung Foundation, European Research Council. ER has received funding from Imperial College Biomedical Research Centre. The funders of the studies had no role in the study design, data collection, data analysis, data interpretation, or report preparation. Trial Australian., Background Self-reported adherence to the Mediterranean diet has been modestly inversely associated with incidence of type 2 diabetes (T2D) in cohort studies. There is uncertainty about the validity and magnitude of this association due to subjective reporting of diet. The association has not been evaluated using an objectively measured biomarker of the Mediterranean diet. Methods and findings We derived a biomarker score based on 5 circulating carotenoids and 24 fatty acids that discriminated between the Mediterranean or habitual diet arms of a parallel design, 6-month partial-feeding randomised controlled trial (RCT) conducted between 2013 and 2014, the MedLey trial (128 participants out of 166 randomised). We applied this biomarker score in an observational study, the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, to assess the association of the score with T2D incidence over an average of 9.7 years of follow-up since the baseline (1991 to 1998). We included 22,202 participants, of whom 9,453 were T2D cases, with relevant biomarkers from an original case-cohort of 27,779 participants sampled from a cohort of 340,234 people. As a secondary measure of the Mediterranean diet, we used a score estimated from dietary-self report. Within the trial, the biomarker score discriminated well between the 2 arms; the cross-validated C-statistic was 0.88 (95% confidence interval (CI) 0.82 to 0.94). The score was inversely associated with incident T2D in EPIC-InterAct: the hazard ratio (HR) per standard deviation of the score was 0.71 (95% CI: 0.65 to 0.77) following adjustment for sociodemographic, lifestyle and medical factors, and adiposity. In comparison, the HR per standard deviation of the self-reported Mediterranean diet was 0.90 (95% CI: 0.86 to 0.95). Assuming the score was causally associated with T2D, higher adherence to the Mediterranean diet in Western European adults by 10 percentiles of the score was estimated to reduce the incidence of T2D by 11% (95% CI: 7% to 14%). The study limitations included potential measurement error in nutritional biomarkers, unclear specificity of the biomarker score to the Mediterranean diet, and possible residual confounding. Conclusions These findings suggest that objectively assessed adherence to the Mediterranean diet is associated with lower risk of T2D and that even modestly higher adherence may have the potential to reduce the population burden of T2D meaningfully., EU FP6 programme LSHM_CT_2006_037197, European Commission Framework Programme 7 HEALTH-F2-2012-279233, European Research Council (ERC), World Health Organization, Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Catalan Institute of Oncology - ICO (Spain), Spanish Government 701708, Marie Curie Actions 701708, European Union's Horizon 2020, Marie Sklodowska-Curie 701708
- Published
- 2023
11. Supplementary Tables 1-6 from Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Melissa Merritt, Sabina Rinaldi, Mark Gunter, Laure Dossus, Ruth Travis, Kay Tee Khaw, Pilar Amiano, Eva Ardanaz, Maria-Dolores Chirlaque, Maria-José Sánchez, Antonio Agudo, Elisabete Weiderpass, Petra H. Peeters, Carla H. van Gils, H.B(as). Bueno-de-Mesquita, Carlotta Sacerdote, Rosario Tumino, Amalia Mattiello, Valeria Pala, Domenico Palli, Antonia Trichopoulou, Eleni-Maria Papatesta, Pagona Lagiou, Heiner Boeing, Marina Kvaskoff, Mathilde His, Marie-Christine Boutron-Ruault, Anne Tjønneland, Marianne Holm, Kim Overvad, Theron Johnson, Helena Schock, and Danja Sarink
- Abstract
Supplementary table 1. Correlations of sRANKL and the sRANKL/OPG ratio with select hormones among controls: EPIC cohort nested case-control study. Supplementary table 2. Distribution of covariates by quintiles of sRANKL. Supplementary table 3. Circulating concentrations of sRANKL and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 4. The sRANKL/OPG ratio and breast cancer risk by hormone-receptor subtype and menopausal status at blood collection. Supplementary table 5. sRANKL additionally adjusted for continuous (log2) OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study. Supplementary table 6. sRANKL/OPG cross-classification based on median split of sRANKL and OPG and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study.
- Published
- 2023
12. Supplementary Figure 1 from Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
- Author
-
Rudolf Kaaks, Elio Riboli, David Cox, Afshan Siddiq, Isabelle Romieu, Naomi E. Allen, Timothy J. Key, Nick Wareham, Kay-Tee Khaw, Petra H. Peeters, Carla H. van Gils, Martine M. Ros, Bas Bueno-de-Mesquita, Eva Ardanaz, Pilar Amiano, Maria-José Sánchez, Genevieve Buckland, Laudina Rodríguez, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Vittorio Krogh, Domenico Palli, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Madlen Schütze, Heiner Boeing, Alina Vrieling, Jenny Chang-Claude, Françoise Clavel-Chapelon, Pierre Engel, Sylvie Mesrine, Kim Overvad, Anja Olsen, Anne Tjønneland, Sabina Rinaldi, Susen Becker, Laure Dossus, Annekatrin Lukanova, and Rebecca E. James
- Abstract
PDF file - 551K
- Published
- 2023
13. Perspective on This Article from Anthropometric Measures, Physical Activity, and Risk of Glioma and Meningioma in a Large Prospective Cohort Study
- Author
-
Elio Riboli, Paolo Vineis, Isabelle Romieu, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Signe Borgquist, Jonas Manjer, Beatrice S. Melin, Göran Hallmans, Eric J. Duell, Laudina Rodríguez, Maria José Sánchez, Miren Dorronsoro, Maria-Dolores Chirlaque, Aurelio Barricarte, Anne M. May, Petra H. M. Peeters, H. Bas Bueno-de-Mesquita, Amalia Mattiello, Rosario Tumino, Domenico Palli, Claudia Agnoli, Carlotta Sacerdote, Andreas Kyrozis, Christina Bamia, Antonia Trichopoulou, Annika Steffen, Heiner Boeing, Brigit Teucher, Christina C. Dahm, Kim Overvad, Anja Olsen, Anne Tjønneland, Brigitte Schlehofer, Valentina Gallo, Gerald Bové, and Dominique S. Michaud
- Abstract
Perspective on This Article from Anthropometric Measures, Physical Activity, and Risk of Glioma and Meningioma in a Large Prospective Cohort Study
- Published
- 2023
14. Data from Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
- Author
-
Rudolf Kaaks, Elio Riboli, David Cox, Afshan Siddiq, Isabelle Romieu, Naomi E. Allen, Timothy J. Key, Nick Wareham, Kay-Tee Khaw, Petra H. Peeters, Carla H. van Gils, Martine M. Ros, Bas Bueno-de-Mesquita, Eva Ardanaz, Pilar Amiano, Maria-José Sánchez, Genevieve Buckland, Laudina Rodríguez, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Vittorio Krogh, Domenico Palli, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Madlen Schütze, Heiner Boeing, Alina Vrieling, Jenny Chang-Claude, Françoise Clavel-Chapelon, Pierre Engel, Sylvie Mesrine, Kim Overvad, Anja Olsen, Anne Tjønneland, Sabina Rinaldi, Susen Becker, Laure Dossus, Annekatrin Lukanova, and Rebecca E. James
- Abstract
Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case–control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone–binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62–5.23), Ptrend = 0.002; testosterone OR = 2.27 (95% CI: 1.35–3.81), Ptrend = 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00–4.46), Ptrend = 0.05; testosterone OR = 2.06 (95% CI: 0.95–4.46), Ptrend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor–negative as well as receptor–positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors. Cancer Prev Res; 4(10); 1626–35. ©2011 AACR.
- Published
- 2023
15. Supplementary Figure Legend from Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor–Positive and -Negative Breast Cancer: a Nested Case–Control Study
- Author
-
Rudolf Kaaks, Elio Riboli, David Cox, Afshan Siddiq, Isabelle Romieu, Naomi E. Allen, Timothy J. Key, Nick Wareham, Kay-Tee Khaw, Petra H. Peeters, Carla H. van Gils, Martine M. Ros, Bas Bueno-de-Mesquita, Eva Ardanaz, Pilar Amiano, Maria-José Sánchez, Genevieve Buckland, Laudina Rodríguez, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Vittorio Krogh, Domenico Palli, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Madlen Schütze, Heiner Boeing, Alina Vrieling, Jenny Chang-Claude, Françoise Clavel-Chapelon, Pierre Engel, Sylvie Mesrine, Kim Overvad, Anja Olsen, Anne Tjønneland, Sabina Rinaldi, Susen Becker, Laure Dossus, Annekatrin Lukanova, and Rebecca E. James
- Abstract
PDF file - 54K
- Published
- 2023
16. Physical activity attenuates but does not eliminate coronary heart disease risk amongst adults with risk factors: EPIC-CVD case-cohort study
- Author
-
Melony C Fortuin-de Smidt, Maquins Odhiambo Sewe, Camille Lassale, Elisabete Weiderpass, Jonas Andersson, José María Huerta, Ulf Ekelund, Krasimira Aleksandrova, Tammy YN Tong, Christina C Dahm, Anne Tjønneland, Cecilie Kyrø, Karen Steindorf, Matthias B Schulze, Verena Katzke, Carlotta Sacerdote, Claudia Agnoli, Giovanna Masala, Rosario Tumino, Salvatore Panico, Jolanda MA Boer, N Charlotte Onland-Moret, GC Wanda Wendel-Vos, Yvonne T van der Schouw, Kristin Benjaminsen Borch, Antonio Agudo, Dafina Petrova, María Dolores Chirlaque, Moreno Iribas Conchi, Pilar Amiano, Olle Melander, Alicia K Heath, Dagfinn Aune, Nita G Forouhi, Claudia Langenberg, Soren Brage, Elio Riboli, Nicholas J Wareham, John Danesh, Adam S Butterworth, Patrik Wennberg, Forouhi, Nita [0000-0002-5041-248X], Langenberg, Claudia [0000-0002-5017-7344], Brage, Soren [0000-0002-1265-7355], Wareham, Nicholas [0000-0003-1422-2993], Danesh, John [0000-0003-1158-6791], Butterworth, Adam [0000-0002-6915-9015], and Apollo - University of Cambridge Repository
- Subjects
Adult ,Cardiac & Cardiovascular Systems ,population preventable fraction ,Epidemiology ,Hypercholesterolemia ,QUESTIONNAIRE ,physical activity ,BLOOD-PRESSURE ,EXERCISE ,Coronary Disease ,ALL-CAUSE ,Cohort Studies ,Risk Factors ,Humans ,risk factors ,Obesity ,Prospective Studies ,coronary heart disease ,Exercise ,POPULATION ,Science & Technology ,Physical activity ,MORTALITY ,Incidence ,Public Health, Global Health, Social Medicine and Epidemiology ,ASSOCIATION ,PREVENTION ,case-cohort study ,Coronary heart disease ,Population preventable fraction ,Risk factors ,Case-cohort study ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,CARDIOVASCULAR-DISEASE ,Hypertension ,Cardiovascular System & Cardiology ,LIFE-STYLE ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine - Abstract
Aims This study aimed to evaluate the association between physical activity and the incidence of coronary heart disease (CHD) in individuals with and without CHD risk factors. Methods and results EPIC-CVD is a case-cohort study of 29 333 participants that included 13 582 incident CHD cases and a randomly selected sub-cohort nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Self-reported physical activity was summarized using the Cambridge physical activity index (inactive, moderately inactive, moderately active, and active). Participants were categorized into sub-groups based on the presence or the absence of the following risk factors: obesity (body mass index ≥30 kg/m2), hypercholesterolaemia (total cholesterol ≥6.2 mmol/L), history of diabetes, hypertension (self-reported or ≥140/90 mmHg), and current smoking. Prentice-weighted Cox regression was used to assess the association between physical activity and incident CHD events (non-fatal and fatal). Compared to inactive participants without the respective CHD risk factor (referent), excess CHD risk was highest in physically inactive and lowest in moderately active participants with CHD risk factors. Corresponding excess CHD risk estimates amongst those with obesity were 47% [95% confidence interval (CI) 32–64%] and 21% (95%CI 2–44%), with hypercholesterolaemia were 80% (95%CI 55–108%) and 48% (95%CI 22–81%), with hypertension were 80% (95%CI 65–96%) and 49% (95%CI 28–74%), with diabetes were 142% (95%CI 63–260%), and 100% (95%CI 32–204%), and amongst smokers were 152% (95%CI 122–186%) and 109% (95%CI 74–150%). Conclusions In people with CHD risk factors, moderate physical activity, equivalent to 40 mins of walking per day, attenuates but does not completely offset CHD risk.
- Published
- 2022
17. Male breast cancer after childhood cancer
- Author
-
Yuehan Wang, Raoul C. Reulen, Leontien C.M. Kremer, Florent de Vathaire, Riccardo Haupt, Lorna Zadravec Zaletel, Francesca Bagnasco, Charlotte Demoor-Goldschmidt, Willem J. van Dorp, Nadia Haddy, Lars Hjorth, Zsuzsanna Jakab, Claudia E. Kuehni, Päivi M. Lähteenmäki, Helena J.H. van der Pal, Carlotta Sacerdote, Roderick Skinner, Monica Terenziani, Finn Wesenberg, Jeanette F. Winther, Flora E. van Leeuwen, Mike M. Hawkins, Jop C. Teepen, Elvira C. van Dalen, Cécile M. Ronckers, Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, and ARD - Amsterdam Reproduction and Development
- Subjects
Adult ,Male ,Cancer Research ,Data analyses ,Incidence ,Late effects ,Breast Neoplasms, Male ,Childhood cancer survivors ,Male breast cancer ,Cohort Studies ,Oncology ,Cancer Survivors ,Risk Factors ,Second cancer ,Neoplasms ,Systematic review ,Humans ,Female ,Registries ,610 Medicine & health ,Child ,Cohort study ,360 Social problems & social services - Abstract
BACKGROUND Breast cancer is a well-recognised late adverse effect in female childhood cancer survivors (CCSs), especially after chest radiotherapy; information on subsequent male breast cancer (SMBC) is limited. We summarised the existing evidence on SMBC after childhood cancer in a systematic review��and investigated the risk of SMBC among males in a Pan-European cohort. METHODS We searched Medline/PubMed for cohort studies and case reports/series that assessed SMBC after childhood cancer (���21 years). Furthermore, we analysed data on SMBC in the PanCareSurFup cohort, reporting standardised incidence ratios (SIRs), absolute excess risks (AERs), and 5- and 10-year survival rates. RESULTS The systematic review included 38 of 7080 potentially eligible articles. Cohort-specific SMBC frequencies were 0-0.40% (31 studies). SMBC occurred after a follow-up ranging from 24.0 to 42.0 years. Nine case reports/series described 11 SMBC cases, occurring 11.0-42.5 years after primary childhood cancer. In the PanCareSurFup cohort (16 SMBC/37,738 males; 0.04%), we observed a 22.3-fold increased risk of SMBC relative to the general male population (95% CI 12.7-36.2; absolute excess risk/100,000 person-years: 2.3, 95% CI 1.3-3.7). The five- and ten-year survival rates after SMBC diagnosis were 60.3% (95% CI 35.6%-85.0%) and 43.0% (95% CI 16.1%-69.9%), respectively. Clear evidence of risk factors did not emerge from these comprehensive efforts. CONCLUSIONS Compared to the general population, male CCSs have an elevated risk of developing subsequent breast cancer, although the absolute risk is low. Health care providers should be aware of this rare yet serious late effect; male CCSs with symptoms potentially related to SMBC warrant careful examination.
- Published
- 2022
18. Data from Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII
- Author
-
Marc J. Gunter, Elio Riboli, Chirag J. Patel, Isabelle Romieu, Sabina Rinaldi, Ruth C. Travis, Nicholas Wareham, Kay-Tee Khaw, Annika Idahl, Lena Maria Nilsson, Emily Sonestedt, Ulrica Ericson, Saioa Chamosa, Aurelio Barricarte, D. Salmerón, María-José Sánchez, Eric J. Duell, J. Ramón Quirós, Guri Skeie, Inger T. Gram, Petra H. Peeters, N. Charlotte Onland-Moret, H.B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Sara Grioni, Domenico Palli, Dimitrios Trichopoulos, Christina Bamia, Antonia Trichopoulou, Heiner Boeing, Krasimira Aleksandrova, Rudolf Kaaks, Renée T. Fortner, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Laure Dossus, Kim Overvad, Christina C. Dahm, Kristina E.N. Petersen, Anne Tjønneland, Elisabete Weiderpass, Konstantinos K. Tsilidis, Judy Fernandes, Susan E. Hankinson, Immaculata De Vivo, Shelley S. Tworoger, Ioanna Tzoulaki, and Melissa A. Merritt
- Abstract
Data on the role of dietary factors in endometrial cancer development are limited and inconsistent. We applied a “nutrient-wide association study” approach to systematically evaluate dietary risk associations for endometrial cancer while controlling for multiple hypothesis tests using the false discovery rate (FDR) and validating the results in an independent cohort. We evaluated endometrial cancer risk associations for dietary intake of 84 foods and nutrients based on dietary questionnaires in three prospective studies, the European Prospective Investigation into Cancer and Nutrition (EPIC; N = 1,303 cases) followed by validation of nine foods/nutrients (FDR ≤ 0.10) in the Nurses' Health Studies (NHS/NHSII; N = 1,531 cases). Cox regression models were used to estimate HRs and 95% confidence intervals (CI). In multivariate adjusted comparisons of the extreme categories of intake at baseline, coffee was inversely associated with endometrial cancer risk (EPIC, median intake 750 g/day vs. 8.6; HR, 0.81; 95% CI, 0.68–0.97, Ptrend = 0.09; NHS/NHSII, median intake 1067 g/day vs. none; HR, 0.82; 95% CI, 0.70–0.96, Ptrend = 0.04). Eight other dietary factors that were associated with endometrial cancer risk in the EPIC study (total fat, monounsaturated fat, carbohydrates, phosphorus, butter, yogurt, cheese, and potatoes) were not confirmed in the NHS/NHSII. Our findings suggest that coffee intake may be inversely associated with endometrial cancer risk. Further data are needed to confirm these findings and to examine the mechanisms linking coffee intake to endometrial cancer risk to develop improved prevention strategies. Cancer Epidemiol Biomarkers Prev; 24(2); 466–71. ©2015 AACR.
- Published
- 2023
19. Data from Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort
- Author
-
Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Ruth C. Travis, Timothy J. Key, Kay-Tee Khaw, Marit Waaseth, Eiliv Lund, Elisabete Weiderpass, Eva Lundin, Annika Idahl, N. Charlotte Onland-Moret, Evelyn M. Monninkhof, H. Bas Bueno-de-Mesquita, Aurelio Barricarte, José María Huerta Castaño, Pilar Amiano, Esther Molina-Montes, Soledad Sánchez, Genevieve Buckland, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Claudia Agnoli, Giovanna Masala, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Heiner Boeing, Isabelle Romieu, Sabina Rinaldi, Laura Baglietto, Kim Overvad, Anja Olsen, Anne Tjønneland, Françoise Clavel-Chapelon, Laure Dossus, Theron Johnson, Disorn Sookthai, and Kaja Tikk
- Abstract
Background: Experimental and epidemiologic data suggest that higher circulating prolactin is associated with breast cancer risk; however, how various risk factors for breast cancer influence prolactin levels in healthy women is not clear.Methods: We analyzed cross-sectional associations between several suggested reproductive and lifestyle risk factors for breast cancer and circulating prolactin among pre- and postmenopausal women, taking into account the use of current postmenopausal hormone therapy, among 2,560 controls from a breast cancer nested case–control study within the EPIC cohort.Results: Adjusted geometric mean prolactin levels were significantly higher among premenopausal women, and among postmenopausal women using hormone therapy compared with nonusers (8.2, 7.0, and 6.3 ng/mL, respectively; Pcat = Pcat = 0.001). Prolactin levels were lower among parous women compared with nulliparous women (8.61 vs. 10.95 ng/mL; Pcat = 0.0002, premenopausal women); the magnitude of this difference depended on the number of full-term pregnancies (22.1% lower, ≥3 vs. 1 pregnancy, Ptrend = 0.01). Results for parity were similar but lower in magnitude among postmenopausal women. Prolactin did not vary by other studied factors, with the exception of lower levels among postmenopausal smokers compared with never smokers.Conclusions: Our study shows that current hormone therapy use, especially the use of combined hormone therapy, is associated with higher circulating prolactin levels in postmenopausal women, and confirms prior findings of lower circulating prolactin in parous women.Impact: Our study extends the knowledge linking various breast cancer risk factors with circulating prolactin. Cancer Epidemiol Biomarkers Prev; 23(11); 2532–42. ©2014 AACR.
- Published
- 2023
20. Supplementary Table S2 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Table S2. TL quartiles and OS association analysis (Crude Cox regression).
- Published
- 2023
21. Supplementary Figure S1 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Figure S1. Kaplan-Meier OS curves of bladder cancer patients stratified for TL quartiles. OS, overall survival; TL, telomere length.
- Published
- 2023
22. Data from Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
- Author
-
Marc Chadeau-Hyam, Roel C.H. Vermeulen, Torkjel M. Sandanger, Mattias Johansson, Paolo Vineis, Augustin Scalbert, Pekka Keski-Rahkonen, Mikael Johansson, Matthias B. Schulze, Rosario Tumino, Salvatore Panico, Carlotta Sacerdote, Domenico Palli, Claudia Agnoli, Therese Haugdahl Nøst, Matthew D. Whitaker, Dusan Petrovic, Karl Smith-Byrne, Florence Guida, Barbara Bodinier, and Sonia Dagnino
- Abstract
Increasing evidence points to a role for inflammation in lung carcinogenesis. A small number of circulating inflammatory proteins have been identified as showing elevated levels prior to lung cancer diagnosis, indicating the potential for prospective circulating protein concentration as a marker of early carcinogenesis. To identify novel markers of lung cancer risk, we measured a panel of 92 circulating inflammatory proteins in 648 prediagnostic blood samples from two prospective cohorts in Italy and Norway (women only). To preserve the comparability of results and protect against confounding factors, the main statistical analyses were conducted in women from both studies, with replication sought in men (Italian participants). Univariate and penalized regression models revealed for the first time higher blood levels of CDCP1 protein in cases that went on to develop lung cancer compared with controls, irrespective of time to diagnosis, smoking habits, and gender. This association was validated in an additional 450 samples. Associations were stronger for future cases of adenocarcinoma where CDCP1 showed better explanatory performance. Integrative analyses combining gene expression and protein levels of CDCP1 measured in the same individuals suggested a link between CDCP1 and the expression of transcripts of LRRN3 and SEM1. Enrichment analyses indicated a potential role for CDCP1 in pathways related to cell adhesion and mobility, such as the WNT/β-catenin pathway. Overall, this study identifies lung cancer–related dysregulation of CDCP1 expression years before diagnosis.Significance:Prospective proteomics analyses reveal an association between increased levels of circulating CDCP1 and lung carcinogenesis irrespective of smoking and years before diagnosis, and integrating gene expression indicates potential underlying mechanisms.See related commentary by Itzstein et al., p. 3441.
- Published
- 2023
23. Supplemental tables 1 and 2 from Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Melissa A. Merritt, Isabelle Romieu, Sabina Rinaldi, Kay-Tee Khaw, Ruth C. Travis, Annika Idahl, Eva Lundin, Jenny Brändstedt, Eva Ardanaz, José María Huerta Castaño, Nerea Larrañaga, Maria-José Sànchez-Pérez, Mireia Obon-Santacana, Soledad Sánchez, Inger T. Gram, Elisabete Weiderpass, N. Charlotte Onland-Moret, Petra H. M. Peeters, H. B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Giovanna Tagliabue, Giovanna Masala, Pagona Lagiou, Vassiliki Benetou, Antonia Trichopolou, Heiner Boeing, Laura Baglietto, Françoise Clavel-Chapelon, Laure Dossus, Kim Overvad, Louise Hansen, Anne Tjønneland, Helena Schock, and Jennifer Ose
- Abstract
Supplemental tables 1 and 2. Supplementary Table 1. Odds ratios (95% CI) for ovarian cancer by tertile concentrations and for doubling in CRP and IL-6 by menopausal status, age at diagnosis and HRT use at blood donation. Supplementary Table 2. Odds ratios (95% CI) for ovarian cancer for doubling in CRP and IL-6 by BMI categories and waist circumference, mutual adjusted for IL-6 and CRP.
- Published
- 2023
24. Supplementary Tables S1-S3 from Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort
- Author
-
Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Ruth C. Travis, Timothy J. Key, Kay-Tee Khaw, Marit Waaseth, Eiliv Lund, Elisabete Weiderpass, Eva Lundin, Annika Idahl, N. Charlotte Onland-Moret, Evelyn M. Monninkhof, H. Bas Bueno-de-Mesquita, Aurelio Barricarte, José María Huerta Castaño, Pilar Amiano, Esther Molina-Montes, Soledad Sánchez, Genevieve Buckland, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Claudia Agnoli, Giovanna Masala, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Heiner Boeing, Isabelle Romieu, Sabina Rinaldi, Laura Baglietto, Kim Overvad, Anja Olsen, Anne Tjønneland, Françoise Clavel-Chapelon, Laure Dossus, Theron Johnson, Disorn Sookthai, and Kaja Tikk
- Abstract
Supplementary Table S1. Adjusteda geometric mean prolactin levels, ng/ml (95% CI) by established correlates at the time of blood donation. Supplementary Table S2. Adjusteda geometric mean prolactin levels, ng/ml (95% CI) depending on the anthropometric factors. Supplementary Table S3. Adjusteda geometric mean prolactin levels, ng/ml (95% CI) depending on the lifestyle factors.
- Published
- 2023
25. Supplementary Methods from Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of Lung Cancer in EPIC
- Author
-
Paul Brennan, Paolo Vineis, Elio Riboli, Göran Hallmans, Torgny Rasmuson, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Giovanna Masala, Vittorio Krogh, Teresa Norat, Valentina Gallo, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Nerea Larrañaga, Maria-José Sánchez, Laudina Rodríguez, Jose-Maria Huerta, Aurelio Barricarte, Antonio Agudo, Petra H.M. Peeters, Carla van Gils, H. Bas Bueno-de-Mesquita, Cornelia Weikert, Heiner Boeing, Birgit Teucher, Rudolf Kaaks, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Isabelle Romieu, Nadia Slimani, Ottar Nygård, Øivind Midttun, Stein Emil Vollset, Per Magne Ueland, Caroline Relton, Amélie Chabrier, Graham B. Byrnes, Mattias Johansson, Smith George Davey, James D. McKay, and Maria N. Timofeeva
- Abstract
PDF file - 82K
- Published
- 2023
26. Supplementary Tables 1-2 from Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of Lung Cancer in EPIC
- Author
-
Paul Brennan, Paolo Vineis, Elio Riboli, Göran Hallmans, Torgny Rasmuson, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Giovanna Masala, Vittorio Krogh, Teresa Norat, Valentina Gallo, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Nerea Larrañaga, Maria-José Sánchez, Laudina Rodríguez, Jose-Maria Huerta, Aurelio Barricarte, Antonio Agudo, Petra H.M. Peeters, Carla van Gils, H. Bas Bueno-de-Mesquita, Cornelia Weikert, Heiner Boeing, Birgit Teucher, Rudolf Kaaks, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Isabelle Romieu, Nadia Slimani, Ottar Nygård, Øivind Midttun, Stein Emil Vollset, Per Magne Ueland, Caroline Relton, Amélie Chabrier, Graham B. Byrnes, Mattias Johansson, Smith George Davey, James D. McKay, and Maria N. Timofeeva
- Abstract
PDF file - 57K
- Published
- 2023
27. Supplemental Material and Methods, Tables S1-S6, Figure S1 from Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII
- Author
-
Marc J. Gunter, Elio Riboli, Chirag J. Patel, Isabelle Romieu, Sabina Rinaldi, Ruth C. Travis, Nicholas Wareham, Kay-Tee Khaw, Annika Idahl, Lena Maria Nilsson, Emily Sonestedt, Ulrica Ericson, Saioa Chamosa, Aurelio Barricarte, D. Salmerón, María-José Sánchez, Eric J. Duell, J. Ramón Quirós, Guri Skeie, Inger T. Gram, Petra H. Peeters, N. Charlotte Onland-Moret, H.B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Sara Grioni, Domenico Palli, Dimitrios Trichopoulos, Christina Bamia, Antonia Trichopoulou, Heiner Boeing, Krasimira Aleksandrova, Rudolf Kaaks, Renée T. Fortner, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Laure Dossus, Kim Overvad, Christina C. Dahm, Kristina E.N. Petersen, Anne Tjønneland, Elisabete Weiderpass, Konstantinos K. Tsilidis, Judy Fernandes, Susan E. Hankinson, Immaculata De Vivo, Shelley S. Tworoger, Ioanna Tzoulaki, and Melissa A. Merritt
- Abstract
Supplemental Material and Methods, Tables S1-S6, Figure S1 Supplemental Table S1. Hazard Ratiosa and 95% CIs from analyses of nutrient and food intakes (FDR≤0.10) reported in the baseline dietary assessment in relation to endometrial cancer risk in the EPIC study. Supplemental Table S2. Hazard Ratiosa and 95% CIs from analyses of intake of nutrients/foods at baseline (FDR > 0.10) in relation to endometrial cancer risk in the EPIC study. Supplemental Table S3. Age-standardized dietary intake of selected foods/nutrients (FDR≤0.10 in the EPIC studya) at the study baseline in the EPIC, NHS and NHSII study populations. Supplemental Table S4. Hazard Ratiosa and 95% CIs from analyses of intake of selected nutrients/foods at baseline in relation to endometrial cancer risk in the Nurses’ Health Study (NHS) and NHSII. Supplemental Table S5. Hazard Ratiosa and 95% CIs from analyses of the cumulative average intake of selected nutrients/foods in relation to endometrial cancer risk in the Nurses’ Health Study (NHS) and NHSII. Supplemental Table S6. Hazard Ratiosa and 95% CIs from analyses of the cumulative average intake of selected nutrients/foods in relation to invasive endometrial adenocarcinoma risk in the Nurses’ Health Study (NHS) and NHSII. Supplemental Figure S1. Summary of NWAS analytical method to test associations between food and nutrient intake and risk of endometrial cancer (EC.
- Published
- 2023
28. Data from Genetic Polymorphisms in 15q25 and 19q13 Loci, Cotinine Levels, and Risk of Lung Cancer in EPIC
- Author
-
Paul Brennan, Paolo Vineis, Elio Riboli, Göran Hallmans, Torgny Rasmuson, Dimitrios Trichopoulos, Pagona Lagiou, Antonia Trichopoulou, Rosario Tumino, Carlotta Sacerdote, Salvatore Panico, Giovanna Masala, Vittorio Krogh, Teresa Norat, Valentina Gallo, Ruth C. Travis, Naomi E. Allen, Nick Wareham, Kay-Tee Khaw, Nerea Larrañaga, Maria-José Sánchez, Laudina Rodríguez, Jose-Maria Huerta, Aurelio Barricarte, Antonio Agudo, Petra H.M. Peeters, Carla van Gils, H. Bas Bueno-de-Mesquita, Cornelia Weikert, Heiner Boeing, Birgit Teucher, Rudolf Kaaks, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Isabelle Romieu, Nadia Slimani, Ottar Nygård, Øivind Midttun, Stein Emil Vollset, Per Magne Ueland, Caroline Relton, Amélie Chabrier, Graham B. Byrnes, Mattias Johansson, Smith George Davey, James D. McKay, and Maria N. Timofeeva
- Abstract
Backgrounds: Multiple polymorphisms affecting smoking behavior have been identified through genome-wide association studies. Circulating levels of the nicotine metabolite cotinine is a marker of recent smoking exposure. Hence, genetic variants influencing smoking behavior are expected to be associated with cotinine levels.Methods: We conducted an analysis in a lung cancer case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We investigated the effects of single-nucleotide polymorphisms (SNP) previously associated with smoking behavior on (i) circulating cotinine and (ii) lung cancer risk. A total of 894 cases and 1,805 controls were analyzed for cotinine and genotyped for 10 polymorphisms on 7p14, 8p11, 10q23, 15q25, and 19q13.Results: Two variants in the nicotinic acetylcholine receptor subunit genes CHRNA5 and CHRNA3 on 15q25, rs16969968 and rs578776, were associated with cotinine (P = 0.001 and 0.03, respectively) in current smokers and with lung cancer risk (P < 0.001 and P = 0.001, respectively). Two 19q13 variants, rs7937 and rs4105144, were associated with increased cotinine (P = 0.003 and P < 0.001, respectively) but decreased lung cancer risk (P = 0.01 for both, after adjusting for cotinine). Variants in 7p14, 8p11, and 10q23 were not associated with cotinine or lung cancer risk.Conclusions: 15q25 and 19q13 SNPs were associated with circulating cotinine. The directions of association for 15q25 variants with cotinine were in accordance with that expected of lung cancer risk, whereas SNPs on 19q13 displayed contrasting associations of cotinine and lung cancer that require further investigation.Impact: This study is the largest to date investigating the effects of polymorphisms affecting smoking behavior on lung cancer risk using circulating cotinine measures as proxies for recent smoking behavior. Cancer Epidemiol Biomarkers Prev; 20(10); 2250–61. ©2011 AACR.
- Published
- 2023
29. Data from Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer
- Author
-
Peter Kraft, Regina G. Ziegler, Elio Riboli, Rudolf Kaaks, Shumin M. Zhang, Meredith Yeager, Walter C. Willett, Stephanie J. Weinstein, Jarmo Virtamo, Rosario Tumino, Dimitrios Trichopoulos, Anne Tjønneland, Michael J. Thun, Gilles Thomas, Daniel O. Stram, Pär Stattin, Meir J. Stampfer, Maria-José Sánchez, Carlotta Sacerdote, Laudina Rodriguez, Kim Overvad, N. Charlotte Onland-Moret, Jing Ma, Eiliv Lund, Loic LeMarchand, I-Min Lee, Pagona Lagiou, Laurence N. Kolonel, Kay-Tee Khaw, Timothy J. Key, Mattias Johansson, Robert N. Hoover, David J. Hunter, Brian E. Henderson, Richard B. Hayes, Susan E. Hankinson, Christopher A. Haiman, Edward L. Giovannucci, J. Michael Gaziano, Vanessa Dumeaux, Françoise Clavel-Chapelon, Stephen J. Chanock, Nathalie Chabbert-Buffet, Julie E. Buring, H. Bas Bueno-de-Mesquita, Heiner Boeing, Sonja I. Berndt, Christine D. Berg, Demetrius Albanes, Naomi E. Allen, Federico Canzian, Fredrick R. Schumacher, and Fangyi Gu
- Abstract
Background: Circulating levels of insulin-like growth factor I (IGF-I) and its main binding protein, IGF binding protein 3 (IGFBP-3), have been associated with risk of several types of cancer. Heritable factors explain up to 60% of the variation in IGF-I and IGFBP-3 in studies of adult twins.Methods: We systematically examined common genetic variation in 18 genes in the IGF signaling pathway for associations with circulating levels of IGF-I and IGFBP-3. A total of 302 single nucleotide polymorphisms (SNP) were genotyped in >5,500 Caucasian men and 5,500 Caucasian women from the Breast and Prostate Cancer Cohort Consortium.Results: After adjusting for multiple testing, SNPs in the IGF1 and SSTR5 genes were significantly associated with circulating IGF-I (P < 2.1 × 10−4); SNPs in the IGFBP3 and IGFALS genes were significantly associated with circulating IGFBP-3. Multi-SNP models explained R2 = 0.62% of the variation in circulating IGF-I and 3.9% of the variation in circulating IGFBP-3. We saw no significant association between these multi-SNP predictors of circulating IGF-I or IGFBP-3 and risk of prostate or breast cancers.Conclusion: Common genetic variation in the IGF1 and SSTR5 genes seems to influence circulating IGF-I levels, and variation in IGFBP3 and IGFALS seems to influence circulating IGFBP-3. However, these variants explain only a small percentage of the variation in circulating IGF-I and IGFBP-3 in Caucasian men and women.Impact: Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes. Cancer Epidemiol Biomarkers Prev; 19(11); 2877–87. ©2010 AACR.
- Published
- 2023
30. Supplementary Table S3 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Table S3. Multivariate Cox regression survival analysis, including TL, age, TG, BCG, radical cystectomy, radiotherapy and chemotherapy. All cause of death.
- Published
- 2023
31. Supplementary Table S1 from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Supplementary Table S1. Description of populations included and not included in the TL study and comparative analysis.
- Published
- 2023
32. Supplementary Data from Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
- Author
-
Marc Chadeau-Hyam, Roel C.H. Vermeulen, Torkjel M. Sandanger, Mattias Johansson, Paolo Vineis, Augustin Scalbert, Pekka Keski-Rahkonen, Mikael Johansson, Matthias B. Schulze, Rosario Tumino, Salvatore Panico, Carlotta Sacerdote, Domenico Palli, Claudia Agnoli, Therese Haugdahl Nøst, Matthew D. Whitaker, Dusan Petrovic, Karl Smith-Byrne, Florence Guida, Barbara Bodinier, and Sonia Dagnino
- Abstract
Supplementary Methods, Figures and Tables.
- Published
- 2023
33. Supplementary Table 1 from Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer
- Author
-
Peter Kraft, Regina G. Ziegler, Elio Riboli, Rudolf Kaaks, Shumin M. Zhang, Meredith Yeager, Walter C. Willett, Stephanie J. Weinstein, Jarmo Virtamo, Rosario Tumino, Dimitrios Trichopoulos, Anne Tjønneland, Michael J. Thun, Gilles Thomas, Daniel O. Stram, Pär Stattin, Meir J. Stampfer, Maria-José Sánchez, Carlotta Sacerdote, Laudina Rodriguez, Kim Overvad, N. Charlotte Onland-Moret, Jing Ma, Eiliv Lund, Loic LeMarchand, I-Min Lee, Pagona Lagiou, Laurence N. Kolonel, Kay-Tee Khaw, Timothy J. Key, Mattias Johansson, Robert N. Hoover, David J. Hunter, Brian E. Henderson, Richard B. Hayes, Susan E. Hankinson, Christopher A. Haiman, Edward L. Giovannucci, J. Michael Gaziano, Vanessa Dumeaux, Françoise Clavel-Chapelon, Stephen J. Chanock, Nathalie Chabbert-Buffet, Julie E. Buring, H. Bas Bueno-de-Mesquita, Heiner Boeing, Sonja I. Berndt, Christine D. Berg, Demetrius Albanes, Naomi E. Allen, Federico Canzian, Fredrick R. Schumacher, and Fangyi Gu
- Abstract
Supplementary Table 1 from Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer
- Published
- 2023
34. Data from Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort
- Author
-
Renée T. Fortner, Rudolf Kaaks, Elio Riboli, Marc J. Gunter, Melissa A. Merritt, Isabelle Romieu, Sabina Rinaldi, Kay-Tee Khaw, Ruth C. Travis, Annika Idahl, Eva Lundin, Jenny Brändstedt, Eva Ardanaz, José María Huerta Castaño, Nerea Larrañaga, Maria-José Sànchez-Pérez, Mireia Obon-Santacana, Soledad Sánchez, Inger T. Gram, Elisabete Weiderpass, N. Charlotte Onland-Moret, Petra H. M. Peeters, H. B(as). Bueno-de-Mesquita, Amalia Mattiello, Carlotta Sacerdote, Rosario Tumino, Giovanna Tagliabue, Giovanna Masala, Pagona Lagiou, Vassiliki Benetou, Antonia Trichopolou, Heiner Boeing, Laura Baglietto, Françoise Clavel-Chapelon, Laure Dossus, Kim Overvad, Louise Hansen, Anne Tjønneland, Helena Schock, and Jennifer Ose
- Abstract
Background: Evidence suggests an etiologic role for inflammation in ovarian carcinogenesis and heterogeneity between tumor subtypes and anthropometric indices. Prospective studies on circulating inflammatory markers and epithelial invasive ovarian cancer (EOC) have predominantly investigated overall risk; data characterizing risk by tumor characteristics (histology, grade, stage, dualistic model of ovarian carcinogenesis) and anthropometric indices are sparse.Methods: We conducted a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate C-reactive protein (CRP), IL6, and EOC risk by tumor characteristics. A total of 754 eligible EOC cases were identified; two controls (n = 1,497) were matched per case. We used multivariable conditional logistic regression to assess associations.Results: CRP and IL6 were not associated with overall EOC risk. However, consistent with prior research, CRP >10 versus CRP ≤1 mg/L was associated with higher overall EOC risk [OR, 1.67 (1.03–2.70)]. We did not observe significant associations or heterogeneity in analyses by tumor characteristics. In analyses stratified by waist circumference, inflammatory markers were associated with higher risk among women with higher waist circumference; no association was observed for women with normal waist circumference [e.g., IL6: waist ≤80: ORlog2, 0.97 (0.81–1.16); waist >88: ORlog2, 1.78 (1.28–2.48), Pheterogeneity ≤ 0.01].Conclusions: Our data suggest that high CRP is associated with increased risk of overall EOC, and that IL6 and CRP may be associated with EOC risk among women with higher adiposity.Impact: Our data add to global evidence that ovarian carcinogenesis may be promoted by an inflammatory milieu. Cancer Epidemiol Biomarkers Prev; 24(6); 951–61. ©2015 AACR.
- Published
- 2023
35. Data from Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer
- Author
-
Giuseppe Matullo, Carlotta Sacerdote, Paolo Vineis, Bruno Frea, Dario Fontana, Andrea Zitella, Luigi Rolle, Paolo Gontero, Paolo Destefanis, Giuseppina Cucchiarale, Giovanni Casetta, Andrea Bosio, Rossana Critelli, Alessandra Allione, Clara Viberti, Barbara Pardini, Giovanni Fiorito, Simonetta Guarrera, Federica Modica, and Alessia Russo
- Abstract
Background: Shorter telomere length (TL) has been reported to be associated with increased risk of early death in elder individuals. Telomere shortening has been also related to chromosomal instability, which may possibly contribute to the development of several types of digestive or urogenital system cancers and smoking-related tumors. Therefore, we investigated the impact of TL on bladder cancer survival.Methods: TL was measured in leukocyte DNA from whole peripheral blood using quantitative real-time PCR in 463 patients with bladder cancer from a total 726 cases who were followed for up to 18 years.Results: Patients with muscle-invasive tumor/any grade had shorter telomere than patients with non–muscle-invasive tumor/high-grade and with non–muscle-invasive tumor/non–high-grade (TL reference 0.7 ± 0.2; vs. respectively, 0.8 ± 0.2, P = 3.4 × 10−2 and 0.8 ± 0.2, P = 3.6 × 10−2). Moreover, patients in the lowest quartiles of TL were associated with decreased survival after diagnosis (log-rank test, P = 3.9 × 10−4). A Cox regression adjusted by age, cancer aggressiveness, Bacillus Calmette-Guérin, radical cystectomy, radiotherapy, and chemotherapy showed an independent effect of TL on bladder cancer survival (HR, 3.9; 95% confidence interval, 1.7–9.1; P = 1.2 × 10−3).Conclusions: Our results suggest that leukocyte TL is only partly related to tumor aggressiveness and that shorter telomeres act as independent prognostic predictor of survival in patients with bladder cancer. TL information may allow to better select therapeutic approaches in patients with the same stage and grade.Impact: Blood leukocyte TL levels could provide an additional noninvasive prognostic marker to better predict survival and personalize therapies in patients with bladder cancer. Cancer Epidemiol Biomarkers Prev; 23(11); 2439–46. ©2014 AACR.
- Published
- 2023
36. Data from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Tobacco smoking is the most important and well-established bladder cancer risk factor and a rich source of chemical carcinogens and reactive oxygen species that can induce damage to DNA in urothelial cells. Therefore, common variation in DNA repair genes might modify bladder cancer risk. In this study, we present results from meta-analyses and pooled analyses conducted as part of the International Consortium of Bladder Cancer. We included data on 10 single nucleotide polymorphisms corresponding to seven DNA repair genes from 13 studies. Pooled analyses and meta-analyses included 5,282 cases and 5,954 controls of non-Latino white origin. We found evidence for weak but consistent associations with ERCC2 D312N [rs1799793; per-allele odds ratio (OR), 1.10; 95% confidence interval (95% CI), 1.01–1.19; P = 0.021], NBN E185Q (rs1805794; per-allele OR, 1.09; 95% CI, 1.01–1.18; P = 0.028), and XPC A499V (rs2228000; per-allele OR, 1.10; 95% CI, 1.00–1.21; P = 0.044). The association with NBN E185Q was limited to ever smokers (interaction P = 0.002) and was strongest for the highest levels of smoking dose and smoking duration. Overall, our study provides the strongest evidence to date for a role of common variants in DNA repair genes in bladder carcinogenesis. [Cancer Res 2009;69(17):6857–64]
- Published
- 2023
37. Supplementary Tables 1-8 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Supplementary Tables 1-8 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Published
- 2023
38. Supplementary Figure Legend from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Supplementary Figure Legend from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Published
- 2023
39. Supplementary Figure 1 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Author
-
Montserrat Garcia-Closas, Sung Shim Lani Park, Cecilia Arici, Marcello Campagna, Angela Carta, Stefano Porru, Peter Rudnai, Rajiv Kumar, Kvetoslava Koppova, Eugen Gurzau, Alessandra Allione, Silvia Polidoro, Simonetta Guarrera, Carlotta Sacerdote, Paolo Vineis, Yu-Tang Gao, Yong-Bing Xiang, Victoria K. Cortessis, Manuela Gago-Dominguez, Amit D. Joshi, Román Corral, Faye Elliot, Jennifer H. Barrett, Ananya Choudhury, Sei Chung Sak, D. Timothy Bishop, Heather H. Nelson, Angeline S. Andrew, Margaret R. Karagas, Xifeng Wu, Stephen Chanock, Nuria Malats, Debra Silverman, Manolis Kogevinas, Nathaniel Rothman, Gunnar Steineck, Zuo-Feng Zhang, Donatella Placidi, Jack A. Taylor, Simone Benhamou, Tony Fletcher, Giuseppe Matullo, Jian-Min Yuan, Anne E. Kiltie, Karl T. Kelsey, Jonine D. Figueroa, Jie Lin, and Mariana C. Stern
- Abstract
Supplementary Figure 1 from Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer
- Published
- 2023
40. Risk of myocardial infarction and stroke after female breast cancer: analysis on a cohort of 1.3 million women
- Author
-
Fulvio Ricceri, Enrica Favaro, Gregory Winston Gilcrease, Sara Claudia Calabrese, Elisa Ferracin, Daniela Di Cuonzo, Alessandra Macciotta, Alberto Catalano, Lucia Dansero, Angelo d’Errico, Pierfrancesco Franco, Gianmauro Numico, Roberto Gnavi, Giuseppe Costa, Eva Pagano, and Carlotta Sacerdote
- Abstract
Background Breast Cancer (BC) is a leading public-health issue affecting women on a global scale, accounting for about 500,000 new cases every year in Europe. Thanks to the widespread implementation of screening programs and the improvement in therapies, women with BC live longer but they also are more likely to experience an increased risk of other diseases, including second primary cancer, cardiovascular, and metabolic diseases. Reasons for this increased risk include genetics, shared risk factors, and adverse effects from BC treatment. Methods To analyse the risk of myocardial infarction (MI) and stroke in women with BC considering the potential side effects of treatments, we used data from the Piedmont Longitudinal Study, an administrative cohort based on the record-linkage among census data and several health-administrative databases to include than 4 million inhabitants of an Italian region. Results Among 1,342,333 women ranging from 30 to 75 years old 19,203 had a BC diagnosis in the follow-up period, of whom 206 experienced a subsequent MI and 203 a stroke. Women with BC showed an increased risk for MI (HR: 1.20; 95%CI: 1.05–1.38) and for stroke (HR: 1.58; 95%CI: 1.38–1.82). Chemotherapy seemed to be the major risk factor for MI in BC women, while no different risk by therapy was found for stroke. Conclusion The results of this study supported the hypothesis about the toxic effect of therapies, suggesting both clinicians to routinely and actively screen for these treatment-related toxicities in women with BC and researchers to prioritize personalized treatments in order to minimize potentially devastating side effects.
- Published
- 2023
41. Dietary Intake of 91 Individual Polyphenols and 5-Year Body Weight Change in the EPIC-PANACEA Cohort
- Author
-
Mercedes Gil-Lespinard, Jazmín Castañeda, Enrique Almanza-Aguilera, Jesús Humberto Gómez, Anne Tjønneland, Cecilie Kyrø, Kim Overvad, Verena Katzke, Matthias B. Schulze, Giovanna Masala, Claudia Agnoli, Maria Santucci de Magistris, Rosario Tumino, Carlotta Sacerdote, Guri Skeie, Cristina Lasheras, Esther Molina-Montes, José María Huerta, Aurelio Barricarte, Pilar Amiano, Emily Sonestedt, Marisa da Silva, Ingegerd Johansson, Johan Hultdin, Anne M. May, Nita G. Forouhi, Alicia K. Heath, Heinz Freisling, Elisabete Weiderpass, Augustin Scalbert, Raul Zamora-Ros, Almanza-Aguilera, Enrique [0000-0002-4805-0774], Kyrø, Cecilie [0000-0002-9083-8960], Masala, Giovanna [0000-0002-5758-9069], Tumino, Rosario [0000-0003-2666-414X], Sacerdote, Carlotta [0000-0002-8008-5096], Skeie, Guri [0000-0003-2476-4251], Molina-Montes, Esther [0000-0002-0428-2426], Huerta, José María [0000-0002-9637-3869], Sonestedt, Emily [0000-0002-0747-4562], da Silva, Marisa [0000-0003-1215-8625], Johansson, Ingegerd [0000-0002-9227-8434], Hultdin, Johan [0000-0002-9599-0961], Heath, Alicia K [0000-0001-6517-1300], Freisling, Heinz [0000-0001-8648-4998], Weiderpass, Elisabete [0000-0003-2237-0128], Zamora-Ros, Raul [0000-0002-6236-6804], and Apollo - University of Cambridge Repository
- Subjects
obesity ,Nutrition and Dietetics ,polyphenol ,intake ,body weight ,cohort ,EPIC ,Physiology ,Estrès oxidatiu ,Clinical Biochemistry ,Pes corporal ,Polyphenols ,Cell Biology ,Biochemistry ,Article ,Näringslära ,Oxidative stress ,Polifenols ,Obesitat ,Molecular Biology - Abstract
Peer reviewed: True, Funder: International Agency for Research on Cancer (IARC), Funder: Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Funder: NIHR Imperial Biomedical Research Centre (BRC), Funder: Danish Cancer Society (Denmark), Funder: Ligue Contre le Cancer, Funder: Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Funder: Institut National de la Santé et de la Recherche Médicale (INSERM), Funder: German Cancer Aid, Funder: German Cancer Research Center (DKFZ), Funder: German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Funder: Federal Ministry of Education and Research (BMBF), Funder: Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Funder: Compagnia di San Paolo, Funder: National Research Council, Funder: Dutch Ministry of Public Health, Welfare and Sports (VWS), Funder: Netherlands Cancer Registry (NKR), Funder: LK Research Funds, Funder: Dutch Prevention Funds, Funder: Dutch ZON (Zorg Onderzoek Nederland), Funder: World Cancer Research Fund (WCRF), Funder: Statistics Netherlands, Funder: Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Funder: Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, Funder: Catalan Institute of Oncology—ICO, Funder: Swedish Cancer Society, Funder: Swedish Research Council, Funder: County Councils of Skåne and Västerbotten, Polyphenols are bioactive compounds from plants with antioxidant properties that may have a protective role against body weight gain, with adipose tissue and systemic oxidative stress as potential targets. We aimed to investigate the dietary intake of individual polyphenols and their association with 5-year body weight change in a sub-cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC). This study included 349,165 adult participants from nine European countries. Polyphenol intake was estimated through country-specific validated dietary questionnaires and the Phenol-Explorer database. Body weight was obtained at recruitment and after a mean follow-up time of 5 years. Associations were estimated using multilevel mixed linear regression models. From 91 polyphenols included, the majority (n = 67) were inversely associated with 5-year body weight change after FDR-correction (q < 0.05). The greatest inverse associations were observed for quercetin 3-O-rhamnoside (change in weight for doubling in intake: -0.071 (95% CI: -0.085; -0.056) kg/5 years). Only 13 polyphenols showed positive associations with body weight gain, mainly from the subclass hydroxycinnamic acids (HCAs) with coffee as the main dietary source, such as 4-caffeoylquinic acid (0.029 (95% CI: 0.021; 0.038) kg/5 years). Individual polyphenols with fruit, tea, cocoa and whole grain cereals as the main dietary sources may contribute to body weight maintenance in adults. Individual HCAs may have different roles in body weight change depending on their dietary source.
- Published
- 2023
- Full Text
- View/download PDF
42. Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
- Author
-
Ceren Sunguc, Michael M. Hawkins, David L. Winter, Isabelle M. Dudley, Emma J. Heymer, Jop C. Teepen, Rodrigue S. Allodji, Fabiën N. Belle, Francesca Bagnasco, Julianne Byrne, Edit Bárdi, Cécile M. Ronckers, Nadia Haddy, Thorgerdur Gudmundsdottir, Stanislaw Garwicz, Momcilo Jankovic, Helena J. H. van der Pal, Maja Česen Mazić, Christina Schindera, Desiree Grabow, Milena M. Maule, Peter Kaatsch, Melanie Kaiser, Brice Fresneau, Gisela Michel, Roderick Skinner, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Maria Winther Gunnes, Monica Terenziani, Jeanette F. Winther, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Claudia E. Kuehni, Leontien C. Kremer, Riccardo Haupt, Florent de Vathaire, Lars Hjorth, Raoul C. Reulen, Paediatric Oncology, Paediatric Pulmonology, CCA - Cancer Treatment and Quality of Life, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Cancer Research ,Oncology ,360 Social problems & social services ,360 Soziale Probleme, Sozialdienste ,610 Medicine & health ,610 Medizin und Gesundheit - Abstract
Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early., + ID der Publikation: unilu_61255 + Sprache: Englisch + Letzte Aktualisierung: 2022-11-03 12:45:00
- Published
- 2023
43. An Epidemiological Systematic Review with Meta-Analysis on Biomarker Role of Circulating MicroRNAs in Breast Cancer Incidence
- Author
-
Lisa Padroni, Laura De Marco, Lucia Dansero, Valentina Fiano, Lorenzo Milani, Paolo Vasapolli, Luca Manfredi, Saverio Caini, Claudia Agnoli, Fulvio Ricceri, and Carlotta Sacerdote
- Subjects
microRNA ,Organic Chemistry ,General Medicine ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,breast cancer ,blood ,miRNA ,plasma ,serum ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy - Abstract
Breast cancer (BC) is a multifactorial disease caused by an interaction between genetic predisposition and environmental exposures. MicroRNAs are a group of small non-coding RNA molecules, which seem to have a role either as tumor suppressor genes or oncogenes and seem to be related to cancer risk factors. We conducted a systematic review and meta-analysis to identify circulating microRNAs related to BC diagnosis, paying special attention to methodological problems in this research field. A meta-analysis was performed for microRNAs analyzed in at least three independent studies where sufficient data to make analysis were presented. Seventy-five studies were included in the systematic review. A meta-analysis was performed for microRNAs analyzed in at least three independent studies where sufficient data to make analysis were presented. Seven studies were included in the MIR21 and MIR155 meta-analysis, while four studies were included in the MIR10b metanalysis. The pooled sensitivity and specificity of MIR21 for BC diagnosis were 0.86 (95%CI 0.76–0.93) and 0.84 (95%CI 0.71–0.92), 0.83 (95%CI 0.72–0.91) and 0.90 (95%CI 0.69–0.97) for MIR155, and 0.56 (95%CI 0.32–0.71) and 0.95 (95%CI 0.88–0.98) for MIR10b, respectively. Several other microRNAs were found to be dysregulated, distinguishing BC patients from healthy controls. However, there was little consistency between included studies, making it difficult to identify specific microRNAs useful for diagnosis.
- Published
- 2023
44. Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis : results from a cohort study
- Author
-
Carlota Castro-Espin, Catalina Bonet, Marta Crous-Bou, Verena Katzke, Charlotte Le Cornet, Franziska Jannasch, Matthias B. Schulze, Anja Olsen, Anne Tjønneland, Christina C. Dahm, Christian S. Antoniussen, Maria Jose Sánchez, Pilar Amiano, María Dolores Chirlaque, Marcela Guevara, Claudia Agnoli, Rosario Tumino, Carlotta Sacerdote, Maria Santucci De Magistris, Malin Sund, Stina Bodén, Torill Enget Jensen, Karina Standahl Olsen, Guri Skeie, Marc J. Gunter, Sabina Rinaldi, Esther M. Gonzalez-Gil, Elisabete Weiderpass, Sofia Christakoudi, Alicia K. Heath, Laure Dossus, and Antonio Agudo
- Subjects
Cancer Research ,Cancer och onkologi ,Nutrition and Dietetics ,Breast Neoplasms/diagnosis ,Estrogens ,Diet ,Cohort Studies ,Näringslära ,Oncology ,Risk Factors ,Cancer and Oncology ,Humans ,Female ,Prospective Studies - Abstract
BACKGROUND: Inflammatory, insulin and oestrogenic pathways have been linked to breast cancer (BC). We aimed to examine the relationship between pre-diagnostic dietary patterns related to these mechanisms and BC survival. METHODS: The diabetes risk reduction diet (DRRD), inflammatory score of diet (ISD) and oestrogen-related dietary pattern (ERDP) were calculated using dietary data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional hazards models were used to assess associations between dietary patterns and overall mortality and competing risk models for associations with BC-specific mortality. RESULTS: We included 13,270 BC cases with a mean follow-up after diagnosis of 8.6 years, representing 2340 total deaths, including 1475 BC deaths. Higher adherence to the DRRD score was associated with lower overall mortality (HR1–SD 0.92; 95%CI 0.87–0.96). Greater adherence to pro-inflammatory diets was borderline associated with 6% higher mortality HR1–SD 1.06; 95%CI 1.00–1.12. No significant association with the oestrogen-related dietary pattern was observed. None of the dietary patterns were associated with BC-specific mortality. CONCLUSIONS: Greater adherence to an anti-diabetic and anti-inflammatory diet prior to diagnosis is associated with lower overall mortality among BC survivors. Long-term adherence to these dietary patterns could be a means to improve the prognosis of BC survivors., Instituto de Salud Carlos III FI19/00197, European Social Fund (ESF), AECC Scientific Foundation PRYES211366AGUD, World Health Organization, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society, Ligue nationale contre le cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe Helmholtz Association German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) Federal Ministry of Education & Research (BMBF), Fondazione AIRC per la ricerca sul cancro Compagnia di San Paolo Consiglio Nazionale delle Ricerche (CNR), Dutch Ministry of Public Health, Welfare and Sports (VWS) Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds Netherlands Organization for Scientific Research (NWO), World Cancer Research Fund International (WCRF), Netherlands Government, Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra Navarra, Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society Swedish Research Council, County Councils of Skkne, Vasterbotten (Sweden), Cancer Research UK 14136 C8221/A29017, UK Research & Innovation (UKRI), Medical Research Council UK (MRC) 1000143 MR/M012190/1
- Published
- 2023
45. Inflammatory potential of diet and pancreatic cancer risk in the EPIC study
- Author
-
Valerie Cayssials, Genevieve Buckland, Marta Crous-Bou, Catalina Bonet, Elisabete Weiderpass, Guri Skie, Dagfinn Aune, Alicia Heath, Therese Haugdahl Nøst, Giovanna Masala, Claudia Agnoli, Maria Santucci De Magistris, Bas Bueno-de-Mesquita, Jeroen Derksen, Inge Huybrechts, Pietro Ferrari, Oscar Franklin, Stina Bodén, Matthias Schulze, Jose Maria Huerta, Aurelio Barricarte, Carlotta Sacerdote, Pilar Amiano, Rosario Tumino, Esther Molina-Montes, Anne Tjønneland, Cecilie Kyrø, Gianluca Severi, Marie-Christine Boutron-Ruault, Vinciane Rebours, Verena Katzke, Antonio Agudo, and Paula Jakszyn
- Subjects
Pancreatic Neoplasms ,Nutrition and Dietetics ,Risk Factors ,Humans ,Nutritional Status ,Medicine (miscellaneous) ,Prospective Studies ,Diet - Abstract
There is existing evidence on the potential role of chronic inflammation in the pathogenesis of pancreatic cancer (PC) and on how risk may be modulated by dietary factors. Pro-inflammatory diets are suggested to be associated with increased risk of PC but, so far, evidence remains not conclusive. We examined the association between the dietary inflammatory potential and PC risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which includes 450,112 participants.After a 14-year follow-up, a total of 1239 incident PC cases were included in this study. The inflammatory potential of the diet was estimated using an Inflammatory Score of the Diet (ISD). Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between the ISD and PC were estimated using multivariable Cox regression models, adjusted for known risk factors for PC.Participants with higher ISDs had a higher risk of developing PCs. In the fully adjusted multivariate model, the risk of PC increased by 11% (HR 1.11, 95% CI 1.02-1.22) for 1 point each standard deviation increase in the ISD score. Neither obesity nor any other known risk factor for PC showed statistically significant interactions.To the best of our knowledge, this is the first prospective study reporting a positive relationship between the inflammatory potential of diet and PC. Since early diagnosis and treatment of pancreatic cancer might be challenging, prevention remains the major hope for reducing the burden of this disease.
- Published
- 2022
46. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures
- Author
-
Matthias B. Schulze, Anne Tjønneland, Laure Dossus, Sofia Christakoudi, Kim Overvad, Verena Katzke, Roel Vermeulen, Giovanna Masala, Pilar Amiano, Elisabete Weiderpass, José María Huerta, Anja Olsen, Federico Canzian, Valeria Pala, Theron Johnson, Oskar Franklin, Charlotte Le Cornet, Marie-Christine Boutron-Ruault, Salvatore Panico, Eva Ardanaz, Rosario Tumino, Esther Molina-Montes, Bas Bueno-de-Mesquita, Marta Crous-Bou, Sven Olek, Rayaan Mahfouz, Rudolf Kaaks, Aurora Perez-Cornago, Bianca Brauer, Gianluca Severi, Carlotta Sacerdote, Vinciane Rebours, and Malin Sund
- Subjects
Adult ,Male ,Neutrophils ,Epidemiology ,Lymphocyte ,pancreatic cancer ,T-Lymphocytes, Regulatory ,Epigenesis, Genetic ,Immune system ,neutrophils ,Pancreatic cancer ,Biomarkers, Tumor ,Humans ,T-lymphocyte subsets ,Cytotoxic T cell ,Medicine ,Lymphocyte Count ,Prospective Studies ,Prospective cohort study ,Aged ,Aged, 80 and over ,business.industry ,FOXP3 ,Middle Aged ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Causality ,Pancreatic Neoplasms ,EPIC study ,immune system ,medicine.anatomical_structure ,Oncology ,Case-Control Studies ,Immunology ,Female ,business ,CD8 - Abstract
Background: Evidence is accumulating that immune cells play a prominent role in pancreatic cancer etiology but prospective investigations are missing. Methods: We conducted a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) study with 502 pairs of incident pancreatic cancer cases and matched controls. Relative counts of circulating immune cells (neutrophils and lymphocyte sublineages: total CD3+, CD8+, CD4+, and FOXP3+ regulatory T cells (Tregs) relative to nucleated cells, (white blood cells) were measured by qRT-PCR. ORs with 95% confidence intervals were estimated using logistic regressions, modeling relative counts of immune cells on a continuous scale. Results: Neither relative counts of immune cell types taken individually, nor mutually adjusted for each other were associated with pancreatic cancer risks. However, in subgroup analyses by strata of lag-time, higher relative counts of Tregs and lower relative counts of CD8+ were significantly associated with an increased pancreatic cancer risks in participants diagnosed within the first 5 years of follow-up. Conclusions: These results might reflect reverse causation, due to higher relative counts of Tregs and lower counts of CD8+ cells among individuals with more advanced stages of latent pancreatic cancer, who are closer to the point of developing clinical manifest disease. Impact: We have shown, for the first time, that increased relative counts of regulatory T cells and lower relative counts of CD8+, cytotoxic T cells may be associated with pancreatic cancer risk or relatively late-stage tumor development. See related commentary by Michaud and Kelsey, p. 2176
- Published
- 2021
47. Association between classes and subclasses of polyphenol intake and 5‐year body weight changes in the EPIC‐PANACEA study
- Author
-
Jazmin Castañeda, Mercedes Gil‐Lespinard, Enrique Almanza‐Aguilera, Fjorida Llaha, Jesús‐Humberto Gómez, Nicola Bondonno, Anne Tjønneland, Kim Overvad, Verena Katzke, Matthias B. Schulze, Giovanna Masala, Claudia Agnoli, Maria Santucci de Magistris, Rosario Tumino, Carlotta Sacerdote, Guri Skeie, Magritt Brustad, Cristina Lasheras, Esther Molina‐Montes, María‐Dolores Chirlaque, Aurelio Barricarte, Emily Sonestedt, Marisa da Silva, Ingegerd Johansson, Johan Hultdin, Anne M. May, Nita G. Forouhi, Alicia K. Heath, Heinz Freisling, Elisabete Weiderpass, Augustin Scalbert, Raul Zamora‐Ros, Castañeda, Jazmin [0000-0002-8521-9946], Gil-Lespinard, Mercedes [0000-0002-7387-2139], Almanza-Aguilera, Enrique [0000-0002-4805-0774], Llaha, Fjorida [0000-0003-0534-6484], Gómez, Jesús-Humberto [0000-0001-8442-8327], Bondonno, Nicola [0000-0001-5905-444X], Tjønneland, Anne [0000-0003-4385-2097], Overvad, Kim [0000-0001-6429-7921], Katzke, Verena [0000-0002-6509-6555], Schulze, Matthias B [0000-0002-0830-5277], Masala, Giovanna [0000-0002-5758-9069], Agnoli, Claudia [0000-0003-4472-1179], Tumino, Rosario [0000-0003-2666-414X], Sacerdote, Carlotta [0000-0002-8008-5096], Skeie, Guri [0000-0003-2476-4251], Brustad, Magritt [0000-0003-0114-5271], Lasheras, Cristina [0000-0003-0482-4229], Molina-Montes, Esther [0000-0002-0428-2426], Chirlaque, María-Dolores [0000-0001-9242-3040], Barricarte, Aurelio [0000-0001-6750-1270], Sonestedt, Emily [0000-0002-0747-4562], da Silva, Marisa [0000-0003-1215-8625], Johansson, Ingegerd [0000-0002-9227-8434], Hultdin, Johan [0000-0002-9599-0961], Forouhi, Nita G [0000-0002-5041-248X], Heath, Alicia K [0000-0001-6517-1300], Freisling, Heinz [0000-0001-8648-4998], Weiderpass, Elisabete [0000-0003-2237-0128], Scalbert, Augustin [0000-0001-6651-6710], Zamora-Ros, Raul [0000-0002-6236-6804], and Apollo - University of Cambridge Repository
- Subjects
Male ,Flavonoids ,Nutrition and Dietetics ,Coumaric Acids ,Endocrinology, Diabetes and Metabolism ,Body Weight ,Medicine (miscellaneous) ,Polyphenols ,Weight Gain ,Coffee ,Diet ,Näringslära ,Endocrinology ,Neoplasms ,Humans ,Female ,Prospective Studies - Abstract
Objective: The aim of this study was to evaluate the associations among the intake of total polyphenols, polyphenol classes, and polyphenol subclasses and body weight change over 5years. Methods: A total of 349,165 men and women aged 25 to 70years were recruited in the Physical Activity, Nutrition, Alcohol, Cessation of Smoking, Eating Out of Home and Obesity (PANACEA) project of the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort from nine European countries. Body weight was measured at baseline and at follow-up after a median time of 5years. Polyphenol intake, including four main polyphenol classes and eighteen subclasses, was estimated using validated dietary questionnaires and Phenol-Explorer. Multilevel mixed linear regression models were used to estimate the associations. Results: Participants gained, on average, 2.6 kg (5.0 kg) over 5years. Total flavonoids intake was inversely associated with body weight change (-0.195kg/5 years, 95% CI: -0.262 to -0.128). However, the intake of total polyphenols (0.205kg/5 years, 95% CI: 0.138 to 0.272) and intake of hydroxycinnamic acids (0.324kg/5 years, 95% CI: 0.267 to 0.381) were positively associated with body weight gain. In analyses stratified by coffee consumption, hydroxycinnamic acid intake was positively associated with body weight gain in coffee consumers (0.379kg/5 years, 95% CI: 0.319 to 0.440), but not in coffee nonconsumers (-0.179kg/5 years, 95% CI: -0.490 to 0.133). Conclusions: Higher intakes of flavonoids and their subclasses are inversely associated with a modest body weight change. Results regarding hydroxycinnamic acids in coffee consumers require further investigation., Consejo Nacional de Ciencia y Tecnologia (CONACyT) 693636, Instituto de Salud Carlos III CD20/ 00071 CPII20/00009 FI19/00185 PI18/ 00191
- Published
- 2022
48. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses
- Author
-
Liam Gaziano, Luanluan Sun, Matthew Arnold, Steven Bell, Kelly Cho, Stephen K. Kaptoge, Rebecca J. Song, Stephen Burgess, Daniel C. Posner, Katja Mosconi, Cassianne Robinson-Cohen, Amy M. Mason, Thomas R. Bolton, Ran Tao, Elias Allara, Petra Schubert, Lingyan Chen, James R. Staley, Natalie Staplin, Servet Altay, Pilar Amiano, Volker Arndt, Johan Ärnlöv, Elizabeth L.M. Barr, Cecilia Björkelund, Jolanda M.A. Boer, Hermann Brenner, Edoardo Casiglia, Paolo Chiodini, Jackie A. Cooper, Josef Coresh, Mary Cushman, Rachel Dankner, Karina W. Davidson, Renate T. de Jongh, Chiara Donfrancesco, Gunnar Engström, Heinz Freisling, Agustín Gómez de la Cámara, Vilmundur Gudnason, Graeme J. Hankey, Per-Olof Hansson, Alicia K. Heath, Ewout J. Hoorn, Hironori Imano, Simerjot K. Jassal, Rudolf Kaaks, Verena Katzke, Jussi Kauhanen, Stefan Kiechl, Wolfgang Koenig, Richard A. Kronmal, Cecilie Kyrø, Deborah A. Lawlor, Börje Ljungberg, Conor MacDonald, Giovanna Masala, Christa Meisinger, Olle Melander, Conchi Moreno Iribas, Toshiharu Ninomiya, Dorothea Nitsch, Børge G. Nordestgaard, Charlotte Onland-Moret, Luigi Palmieri, Dafina Petrova, Jose Ramón Quirós Garcia, Annika Rosengren, Carlotta Sacerdote, Masaru Sakurai, Carmen Santiuste, Matthias B. Schulze, Sabina Sieri, Johan Sundström, Valérie Tikhonoff, Anne Tjønneland, Tammy Tong, Rosario Tumino, Ioanna Tzoulaki, Yvonne T. van der Schouw, W.M. Monique Verschuren, Henry Völzke, Robert B. Wallace, S. Goya Wannamethee, Elisabete Weiderpass, Peter Willeit, Mark Woodward, Kazumasa Yamagishi, Raul Zamora-Ros, Elvis A. Akwo, Saiju Pyarajan, David R. Gagnon, Philip S. Tsao, Sumitra Muralidhar, Todd L. Edwards, Scott M. Damrauer, Jacob Joseph, Lisa Pennells, Peter W.F. Wilson, Seamus Harrison, Thomas A. Gaziano, Michael Inouye, Colin Baigent, Juan P. Casas, Claudia Langenberg, Nick Wareham, Elio Riboli, J.Michael Gaziano, John Danesh, Adriana M. Hung, Adam S. Butterworth, Angela M. Wood, Emanuele Di Angelantonio, Anna Koettgen, Jonathan Shaw, Robert Atkins, Paul Zimmet, Peter Whincup, Johann Willeit, Christoph Leitner, Anne Tybjaerg-Hansen, Peter Schnohr, Shoaib Afzal, David Lora Pablos, Cristina Martin Arriscado, Carmen Romero Ferreiro, Hannah Stocker, Ben Schöttker, Bernd Holleczek, Angela Chetrit, Lennart Welin, Kurt Svärdsudd, Lauren Lissner, Dominique Hange, Kirsten Mehlig, Dorothea Nagel, Paul E. Norman, Osvaldo Almeida, Leon Flicker, Jun Hata, Takanori Honda, Yoshihiko Furuta, Hiroyasu Iso, Akihiko Kitamura, Isao Muraki, Jukka T. Salonen, Tomi-Pekka Tuomainen, E. M. van Zutphen, N. M. van Schoor, Cinzia Lo Noce, Richard Kronmal, Georg Lappas, Peter M. Nilsson, Bo Hedblad, Jonathan Shaffer, Joseph Schwartz, Daichi Shimbo, Shinichi Sato, Mina Hayama-Terada, Simerjot Jassal, Thor Aspelund, Bolli Thorsson, Gunnar Sigurdsson, Layal Chaker, Kamran M. Ikram, Maryam Kavousi, Hugh Tunstall-Pedoe, Günay Can, Hüsniye Yüksel, Uğur Özkan, Hideaki Nakagawa, Yuko Morikawa, Masao Ishizaki, Edith Feskens, Johanna M Geleijnse, Daan Kromhout, Internal Medicine, Neurology, Epidemiology, Bell, Steven [0000-0001-6774-3149], Posner, Daniel C [0000-0002-3056-6924], Mason, Amy M [0000-0002-8019-0777], Allara, Elias [0000-0002-1634-8330], Staplin, Natalie [0000-0003-4482-4418], Arndt, Volker [0000-0001-9320-8684], Ärnlöv, Johan [0000-0002-6933-4637], Barr, Elizabeth LM [0000-0003-4284-1716], Boer, Jolanda MA [0000-0002-9714-4304], Brenner, Hermann [0000-0002-6129-1572], Casiglia, Edoardo [0000-0002-0003-3289], Chiodini, Paolo [0000-0003-0139-2264], Coresh, Josef [0000-0002-4598-0669], Cushman, Mary [0000-0002-7871-6143], Davidson, Karina W [0000-0002-9162-477X], de Jongh, Renate T [0000-0001-8414-3938], Engström, Gunnar [0000-0002-8618-9152], de la Cámara, Agustín Gómez [0000-0001-6827-6319], Gudnason, Vilmundur [0000-0001-5696-0084], Hankey, Graeme J [0000-0002-6044-7328], Hansson, Per-Olof [0000-0001-6323-0506], Heath, Alicia K [0000-0001-6517-1300], Hoorn, Ewout J [0000-0002-8738-3571], Imano, Hironori [0000-0002-6661-4254], Katzke, Verena [0000-0002-6509-6555], Kiechl, Stefan [0000-0002-9836-2514], Koenig, Wolfgang [0000-0002-2064-9603], Kronmal, Richard A [0000-0002-9897-7076], Kyrø, Cecilie [0000-0002-9083-8960], Ljungberg, Börje [0000-0002-4121-3753], MacDonald, Conor [0000-0002-4989-803X], Masala, Giovanna [0000-0002-5758-9069], Ninomiya, Toshiharu [0000-0003-1345-9032], Nordestgaard, Børge G [0000-0002-1954-7220], Onland-Moret, Charlotte [0000-0002-2360-913X], Palmieri, Luigi [0000-0002-4298-2642], Rosengren, Annika [0000-0002-5409-6605], Schulze, Matthias B [0000-0002-0830-5277], Sieri, Sabina [0000-0001-5201-172X], Sundström, Johan [0000-0003-2247-8454], Tikhonoff, Valérie [0000-0001-7846-0101], Tong, Tammy [0000-0002-0284-8959], Tzoulaki, Ioanna [0000-0002-4275-9328], van der Schouw, Yvonne T [0000-0002-4605-435X], Wannamethee, S Goya [0000-0001-9484-9977], Weiderpass, Elisabete [0000-0003-2237-0128], Willeit, Peter [0000-0002-1866-7159], Woodward, Mark [0000-0001-9800-5296], Yamagishi, Kazumasa [0000-0003-3301-5519], Zamora-Ros, Raul [0000-0002-6236-6804], Gagnon, David R [0000-0002-6367-3179], Tsao, Philip S [0000-0001-7274-9318], Edwards, Todd L [0000-0003-4318-6119], Damrauer, Scott M [0000-0001-8009-1632], Joseph, Jacob [0000-0002-7279-4896], Pennells, Lisa [0000-0002-8594-3061], Gaziano, Thomas A [0000-0002-5985-345X], Langenberg, Claudia [0000-0002-5017-7344], Wareham, Nick [0000-0003-1422-2993], Hung, Adriana M [0000-0002-3203-1608], Butterworth, Adam S [0000-0002-6915-9015], Di Angelantonio, Emanuele [0000-0001-8776-6719], Apollo - University of Cambridge Repository, Gaziano, Liam, Sun, Luanluan, Arnold, Matthew, Bell, Steven, Cho, Kelly, Kaptoge, Stephen K, Song, Rebecca J, Burgess, Stephen, Posner, Daniel C, Mosconi, Katja, Robinson-Cohen, Cassianne, Mason, Amy M, Bolton, Thomas R, Tao, Ran, Allara, Elia, Schubert, Petra, Chen, Lingyan, Staley, James R, Staplin, Natalie, Altay, Servet, Amiano, Pilar, Arndt, Volker, Ärnlöv, Johan, Barr, Elizabeth L M, Björkelund, Cecilia, Boer, Jolanda M A, Brenner, Hermann, Casiglia, Edoardo, Chiodini, Paolo, Cooper, Jackie A, Coresh, Josef, Cushman, Mary, Dankner, Rachel, Davidson, Karina W, de Jongh, Renate T, Donfrancesco, Chiara, Engström, Gunnar, Freisling, Heinz, de la Cámara, Agustín Gómez, Gudnason, Vilmundur, Hankey, Graeme J, Hansson, Per-Olof, Heath, Alicia K, Hoorn, Ewout J, Imano, Hironori, Jassal, Simerjot K, Kaaks, Rudolf, Katzke, Verena, Kauhanen, Jussi, Kiechl, Stefan, Koenig, Wolfgang, Kronmal, Richard A, Kyrø, Cecilie, Lawlor, Deborah A, Ljungberg, Börje, Macdonald, Conor, Masala, Giovanna, Meisinger, Christa, Melander, Olle, Moreno Iribas, Conchi, Ninomiya, Toshiharu, Nitsch, Dorothea, Nordestgaard, Børge G, Onland-Moret, Charlotte, Palmieri, Luigi, Petrova, Dafina, Garcia, Jose Ramón Quiró, Rosengren, Annika, Sacerdote, Carlotta, Sakurai, Masaru, Santiuste, Carmen, Schulze, Matthias B, Sieri, Sabina, Sundström, Johan, Tikhonoff, Valérie, Tjønneland, Anne, Tong, Tammy, Tumino, Rosario, Tzoulaki, Ioanna, van der Schouw, Yvonne T, Monique Verschuren, W M, Völzke, Henry, Wallace, Robert B, Wannamethee, S Goya, Weiderpass, Elisabete, Willeit, Peter, Woodward, Mark, Yamagishi, Kazumasa, Zamora-Ros, Raul, Akwo, Elvis A, Pyarajan, Saiju, Gagnon, David R, Tsao, Philip S, Muralidhar, Sumitra, Edwards, Todd L, Damrauer, Scott M, Joseph, Jacob, Pennells, Lisa, Wilson, Peter W F, Harrison, Seamu, Gaziano, Thomas A, Inouye, Michael, Baigent, Colin, Casas, Juan P, Langenberg, Claudia, Wareham, Nick, Riboli, Elio, Gaziano, J Michael, Danesh, John, Hung, Adriana M, Butterworth, Adam S, Wood, Angela M, Di Angelantonio, Emanuele, Internal medicine, AMS - Ageing & Vitality, AMS - Musculoskeletal Health, Amsterdam Gastroenterology Endocrinology Metabolism, Epidemiology and Data Science, APH - Aging & Later Life, and APH - Personalized Medicine
- Subjects
kidney disease ,General Practice ,Emerging Risk Factors Collaboration/EPIC-CVD/Million Veteran Program ,Coronary Disease ,coronary disease ,Kidney ,Malalties coronàries ,1117 Public Health and Health Services ,Coronary diseases ,SDG 3 - Good Health and Well-being ,cardiovascular disease ,Risk Factors ,Physiology (medical) ,Diabetes Mellitus ,Humans ,Cardiac and Cardiovascular Systems ,Prospective Studies ,1102 Cardiorespiratory Medicine and Haematology ,Kardiologi ,Kidney diseases ,Malalties cardiovasculars ,Cardiovascular Diseases ,Kidney Diseases ,Stroke ,1103 Clinical Sciences ,Mendelian Randomization Analysis ,kidney diseases ,stroke ,Allmänmedicin ,Cardiovascular diseases ,Cardiovascular System & Hematology ,Malalties del ronyó ,Cardiology and Cardiovascular Medicine ,cardiovascular diseases - Abstract
Background: End-stage renal disease is associated with a high risk of cardiovascular events. It is unknown, however, whether mild-to-moderate kidney dysfunction is causally related to coronary heart disease (CHD) and stroke. Methods: Observational analyses were conducted using individual-level data from 4 population data sources (Emerging Risk Factors Collaboration, EPIC-CVD [European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease Study], Million Veteran Program, and UK Biobank), comprising 648 135 participants with no history of cardiovascular disease or diabetes at baseline, yielding 42 858 and 15 693 incident CHD and stroke events, respectively, during 6.8 million person-years of follow-up. Using a genetic risk score of 218 variants for estimated glomerular filtration rate (eGFR), we conducted Mendelian randomization analyses involving 413 718 participants (25 917 CHD and 8622 strokes) in EPIC-CVD, Million Veteran Program, and UK Biobank. Results: There were U-shaped observational associations of creatinine-based eGFR with CHD and stroke, with higher risk in participants with eGFR values 105 mL·min –1 ·1.73 m –2 , compared with those with eGFR between 60 and 105 mL·min –1 ·1.73 m –2 . Mendelian randomization analyses for CHD showed an association among participants with eGFR –1 ·1.73 m –2 , with a 14% (95% CI, 3%–27%) higher CHD risk per 5 mL·min –1 ·1.73 m –2 lower genetically predicted eGFR, but not for those with eGFR >105 mL·min –1 ·1.73 m –2 . Results were not materially different after adjustment for factors associated with the eGFR genetic risk score, such as lipoprotein(a), triglycerides, hemoglobin A1c, and blood pressure. Mendelian randomization results for stroke were nonsignificant but broadly similar to those for CHD. Conclusions: In people without manifest cardiovascular disease or diabetes, mild-to-moderate kidney dysfunction is causally related to risk of CHD, highlighting the potential value of preventive approaches that preserve and modulate kidney function.
- Published
- 2022
49. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort
- Author
-
Alessandra Allione, Clara Viberti, Ilaria Cotellessa, Chiara Catalano, Elisabetta Casalone, Giovanni Cugliari, Alessia Russo, Simonetta Guarrera, Dario Mirabelli, Carlotta Sacerdote, Marco Gentile, Fabian Eichelmann, Matthias B. Schulze, Sophia Harlid, Anne Kirstine Eriksen, Anne Tjønneland, Martin Andersson, Martijn E.T. Dollé, Heleen Van Puyvelde, Elisabete Weiderpass, Miguel Rodriguez‐Barranco, Antonio Agudo, Alicia K. Heath, María‐Dolores Chirlaque, Thérèse Truong, Dzevka Dragic, Gianluca Severi, Sabina Sieri, Torkjel M. Sandanger, Eva Ardanaz, Paolo Vineis, and Giuseppe Matullo
- Subjects
Cancer Research ,DNA methylation ,Oncology ,cancer biomarkers ,mesothelioma ,prospective nested case-control study - Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive non-invasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM pre-diagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 135 participants who developed MPM during 20 years of follow up and from 135 matched, cancer-free, controls. For the discovery phase we selected EPIC participants who developed MPM within five years from enrolment (n=36) with matched controls. We identified nine differentially methylated CpGs, selected by 10-fold cross-validation and correlation analyses: cg25755428 (MRI1), cg20389709 (KLF11), cg23870316, cg13862711 (LHX6), cg06417478 (HOOK2), cg00667948, cg01879420 (AMD1), cg25317025 (RPL17) and cg06205333 (RAP1A). Receiver operating characteristic (ROC) analysis showed that the model including baseline characteristics (age, sex, PC1wbc) along with the nine MPM-related CpGs has a better predictive value for MPM occurrence than the baseline model alone, maintaining some performance also at more than five years before diagnosis [AUC (area under the curve) 10 years=0.75; baseline AUC range=0.63-0.67)]. DNAm changes as non-invasive biomarkers in pre-diagnostic blood samples of MPM cases were investigated for the first time. Their application can improve the identification of asbestos-exposed individuals at higher MPM risk in order to possibly adopt more intensive monitoring for early disease identification.
- Published
- 2022
50. Prediagnostic serum calcium concentrations and risk of colorectal cancer development in 2 large European prospective cohorts
- Author
-
Nena Karavasiloglou, David J. Hughes, Neil Murphy, Lutz Schomburg, Qian Sun, Vartiter Seher, Sabine Rohrmann, Elisabete Weiderpass, Anne Tjønneland, Anja Olsen, Kim Overvad, Marie-Christine Boutron-Ruault, Francesca Romana Mancini, Yahya Mahamat-Saleh, Rudolf Kaaks, Tilman Kuhn, Matthias B. Schulze, Rosario Tumino, Salvatore Panico, Giovanna Masala, Valeria Pala, Carlotta Sacerdote, Jeroen W.G. Derksen, Guri Skeie, Anette Hjartåker, Cristina Lasheras, Antonio Agudo, Maria-José Sánchez, Maria-Dolores Chirlaque, Eva Ardanaz, Pilar Amiano, Bethany Van Guelpen, Björn Gylling, Kathryn E. Bradbury, Keren Papier, Heinz Freisling, Elom K. Aglago, Amanda J. Cross, Elio Riboli, Dagfinn Aune, Marc J. Gunter, and Mazda Jenab
- Subjects
colorectal ,Nutrition and Dietetics ,Medicine (miscellaneous) ,cancer ,cohort ,serum calcium ,risk - Abstract
BACKGROUND: Higher dietary calcium consumption is associated with lower colorectal cancer (CRC) risk. However, little data are available on the association between circulating calcium concentrations and CRC risk.OBJECTIVES: To explore the association between circulating calcium concentrations and CRC risk using data from 2 large European prospective cohort studies.METHODS: Conditional logistic regression models were used to calculate multivariable-adjusted ORs and 95% CIs in case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC; n-cases = 947, n-controls = 947) and the UK Biobank (UK-BB; n-cases = 2759, n-controls = 12,021) cohorts.RESULTS: In EPIC, nonalbumin-adjusted total serum calcium (a proxy of free calcium) was not associated with CRC (OR: 0.94; 95% CI: 0.85, 1.03; modeled as continuous variable, per 1 mg/dL increase), colon cancer (OR: 0.93; 95% CI: 0.82, 1.05) or rectal cancer (OR: 1.01; 95% CI: 0.84, 1.20) risk in the multivariable adjusted model. In the UK-BB, serum ionized calcium (free calcium, most active form) was inversely associated with the risk of CRC (OR: 0.85; 95% CI: 0.76, 0.95; per 1 mg/dL) and colon cancer (OR: 0.78; 95% CI: 0.68, 0.90), but not rectal cancer (OR: 1.02; 95% CI: 0.83, 1.24) in multivariable adjusted models. Meta-analysis of EPIC and UK-BB CRC risk estimates showed an inverse risk association for CRC in the multivariable adjusted model (OR: 0.90; 95%CI: 0.84, 0.97). In analyses by quintiles, in both cohorts, higher levels of serum calcium were associated with reduced CRC risk (EPIC: OR Q5vs.Q1: 0.69; 95% CI: 0.47, 1.00; P-trend = 0.03; UK-BB: OR Q5vs.Q1: 0.82; 95% CI: 0.72, 0.94; P-trend < 0.01). Analyses by anatomical subsite showed an inverse cancer risk association in the colon (EPIC: OR Q5vs.Q1: 0.63, 95% CI: 0.39, 1.02; P-trend = 0.05; UK-BB: OR Q5vs.Q1: 0.75; 95% CI: 0.64, 0.88; P-trend < 0.01) but not the rectum. CONCLUSIONS: In UK-BB, higher serum ionized calcium levels were inversely associated with CRC, but the risk was restricted to the colon. Total serum calcium showed a null association in EPIC. Additional prospective studies in other populations are needed to better investigate these associations.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.